{"fb94b1df339236235d46906ee87e331b27a76694": [["IntroductionIn the last couple of months, world markets' have been hit by an invisible enemy, the novel coronavirus .", [["coronavirus", "DISEASE", 104, 115], ["coronavirus", "ORGANISM", 104, 115], ["IntroductionIn", "TREATMENT", 0, 14], ["the novel coronavirus", "PROBLEM", 94, 115]]], ["The economic activity has suddenly stopped.", [["economic", "OBSERVATION_MODIFIER", 4, 12], ["activity", "OBSERVATION_MODIFIER", 13, 21]]], ["According to scholars, such diseases can have long-lasting effects on economic wealth (e.g. Fogli and Veldkamp, 2013; Goodell, 2020 ).", [["such diseases", "PROBLEM", 23, 36]]], ["Yet, initial impact of more than 20% loss on financial markets' value have been observed.IntroductionThe COVID-19 shock can affect stock markets via two important channels.", [["shock", "DISEASE", 114, 119], ["financial markets' value", "TEST", 45, 69], ["The COVID", "TREATMENT", 101, 110]]], ["First, value of common stocks, theoretically, equals to the present value of expected cash-flows (Aurori and Nguyen, 2010; Azimli, 2020) .", [["common stocks", "ANATOMY", 16, 29]]], ["Due to its spreading patterns and mortality rate, future economic and policy outcomes are highly uncertain.", [["mortality rate", "TEST", 34, 48], ["spreading", "OBSERVATION_MODIFIER", 11, 20]]], ["Second, increased uncertainty affects required rate of return by investors and thus current market value of stocks.", [["increased", "OBSERVATION_MODIFIER", 8, 17], ["uncertainty", "OBSERVATION", 18, 29]]], ["As a result, there has been a sudden shift in investment and consumption patterns.", [["a sudden shift", "PROBLEM", 28, 42]]], ["Such a shift can have important implications on central linearity assumption of models' standard to the asset pricing literature.IntroductionFor instance, Hu (2006) and Koenker (2005) revealed significant impact of crisis on the structure of linear dependence among random variables used to model risk-return relationship.", [["crisis", "PROBLEM", 215, 221], ["linear dependence", "PROBLEM", 242, 259], ["central linearity", "OBSERVATION_MODIFIER", 48, 65], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["crisis", "OBSERVATION", 215, 221], ["linear", "OBSERVATION_MODIFIER", 242, 248]]], ["Quantile regression (QR) approach enables the examination of risk-return relationship at different points (i.e. quantiles) of the dependent variable, y, depending on the conditional median function (see, for instance, Baur.", [["Quantile regression", "PROBLEM", 0, 19], ["the examination", "TEST", 42, 57]]], ["The QR has two major advantages to model risk-return behavior during such events over standard models.", [["QR", "PROTEIN", 4, 6]]], ["Firstly, no distributional assumptions about residuals must be made and the QR is robust to outliers (Baur and Schulze, 2005) .", [["QR", "PROTEIN", 76, 78], ["distributional assumptions about residuals", "PROBLEM", 12, 54]]], ["Secondly, QR can show non-linear properties of dependence among variables and it can provide a broader picture about the impact of shocks on the behavior of entire distribution of y (Yu et al., 2003) .IntroductionThis study adopts the QR regression based methodology suggested by Baur (2013) to examine the impact of COVID-19 on the degree of dependence and structure of risk-return relationship.", [["QR", "PROTEIN", 10, 12], ["This study", "TEST", 213, 223], ["COVID", "TEST", 317, 322], ["non-linear properties", "OBSERVATION_MODIFIER", 22, 43], ["dependence", "OBSERVATION", 47, 57]]], ["Accordingly, a market-based factor model (i.e. CAPM) is augmented with a proxy that accounts for structural shocks and change in dependence.", [["structural shocks", "PROBLEM", 97, 114], ["change in dependence", "PROBLEM", 119, 139], ["structural shocks", "OBSERVATION", 97, 114], ["dependence", "OBSERVATION_MODIFIER", 129, 139]]], ["In addition, Google Search Index for coronavirus (GSIC) is included into the model to proxy overall uncertainty and investor attention fueled by the COVID-19 outbreak.", [["coronavirus", "ORGANISM", 37, 48], ["Google Search Index", "TEST", 13, 32], ["coronavirus", "PROBLEM", 37, 48], ["the COVID", "TEST", 145, 154]]], ["Online search trends have proved to work in predicting pricing and trading patterns of financial assets (e.g. Bijl et al., 2016; Kissian et al., 2011; Takeda and Wakao, 2014; Urquhard, 2018) .Data and sampleThis paper uses daily returns of 10 major sectors of the US 1 .", [["sample", "TEST", 201, 207]]], ["The main co-variates include returns on market portfolio, proxied by daily S&P500 (SP) returns and daily Google Search Index for coronavirus.", [["coronavirus", "PROBLEM", 129, 140], ["main", "OBSERVATION_MODIFIER", 4, 8], ["co-variates", "OBSERVATION", 9, 20]]], ["Notably, mean returns for all the industries and SP are negative with high standard deviations.", [["SP", "PROTEIN", 49, 51], ["high standard deviations", "PROBLEM", 70, 94], ["negative", "OBSERVATION", 56, 64], ["high", "OBSERVATION_MODIFIER", 70, 74], ["standard deviations", "OBSERVATION", 75, 94]]], ["The differences between median and mean values are large.", [["median and mean values", "TEST", 24, 46], ["median", "OBSERVATION_MODIFIER", 24, 30], ["mean values", "OBSERVATION", 35, 46], ["large", "OBSERVATION_MODIFIER", 51, 56]]], ["All returns are leptokurtic indicating extreme values in tails with either right-or left-skewed distributions that are not normal according to Jarque-Bera statistics.", [["extreme values in tails", "PROBLEM", 39, 62], ["extreme values", "OBSERVATION", 39, 53], ["tails", "ANATOMY_MODIFIER", 57, 62], ["right", "ANATOMY_MODIFIER", 75, 80], ["left", "ANATOMY_MODIFIER", 84, 88], ["skewed", "OBSERVATION", 89, 95], ["not", "UNCERTAINTY", 119, 122], ["normal", "OBSERVATION", 123, 129]]], ["These results indicate tail events in returns and thus justify the use of QR.", [["tail", "ANATOMY", 23, 27], ["tail", "ORGANISM_SUBDIVISION", 23, 27], ["QR", "PROTEIN", 74, 76], ["tail events", "PROBLEM", 23, 34], ["tail", "OBSERVATION_MODIFIER", 23, 27]]], ["Note: JB indexes Jarque-Bera test of normality.", [["JB indexes", "TEST", 6, 16]]], ["Figure 1 plots Google searches for coronavirus in the US.", [["coronavirus", "PROBLEM", 35, 46]]], ["It is clearly observable that the index peaks on 12 th of March, one day prior the declaration of national emergency by the president Trump.", [["the index peaks", "PROBLEM", 30, 45], ["index", "OBSERVATION_MODIFIER", 34, 39], ["peaks", "OBSERVATION_MODIFIER", 40, 45]]], ["In addition, on 11 th of March, the virus has declared as pandemic by World Health Organization and on the same day travel from Europe to the US has been restricted.", [["the virus", "PROBLEM", 32, 41]]], ["Breakpoint unit root test of S&P500 series indicated a structural break on 12 th of March 2020.", [["Breakpoint unit root test", "TEST", 0, 25], ["S&P500 series", "TEST", 29, 42]]], ["Accordingly, this date is used to measure structural impact of COVID-19 outbreak on risk-return relationship.ModelThis paper employs panelized QR of Koenker and Basset (1978) to model risk-return relationship in the US during COVID-19 outbreak.", [["QR", "PROTEIN", 143, 145], ["COVID", "TEST", 63, 68], ["the US", "TEST", 212, 218], ["COVID", "TEST", 226, 231]]], ["In addition, methodology of Baur (2013) adopted to measure the impact of COVID-19 outbreak on degree of dependence and structure of risk-return relationship.", [["COVID", "TREATMENT", 73, 78]]], ["Consider a panel QR model as follows:ModelWhere Q(\u03c4|\u2022) denotes a conditional quantile function, is return of industry i at day t, is return on industry i at day t-1, | | is an indicator variable equals to 1 if return on industry i at day t-1 exceeds threshold level, selected as 95 th percentile of unconditional distribution, and zero otherwise.", [["a panel QR model", "TEST", 9, 25]]], ["The SP t, i is return on S&P500 index on day t and GSIC t is Google search index for coronavirus at day t.", [["coronavirus", "DISEASE", 85, 96], ["S&P500", "DNA", 25, 31], ["coronavirus", "PROBLEM", 85, 96]]], ["Finally, the D COVID is a dummy variable intended to measure change in structure and degree of dependence of risk-return relationship during the outbreak.", [["D COVID", "DNA", 13, 20], ["the D COVID", "TREATMENT", 9, 20], ["degree", "OBSERVATION_MODIFIER", 85, 91], ["dependence", "OBSERVATION_MODIFIER", 95, 105]]], ["The and measure average change in degree of dependence of industry returns given SP and GSIC during D COVID .", [["SP", "PROTEIN", 81, 83], ["SP", "PROBLEM", 81, 83], ["D COVID", "TREATMENT", 100, 107], ["average", "OBSERVATION_MODIFIER", 16, 23], ["change", "OBSERVATION_MODIFIER", 24, 30], ["degree", "OBSERVATION_MODIFIER", 34, 40], ["dependence", "OBSERVATION_MODIFIER", 44, 54]]], ["If these coefficients are greater than zero, there is an increase in dependence following the outbreak and vise-versa.", [["these coefficients", "TEST", 3, 21], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["dependence", "OBSERVATION_MODIFIER", 69, 79]]], ["Finally, if and varies across quantiles, there is a change in the structure of dependence.ModelThe QR method of Koenker and Basset (1978) provides the estimates of the degree of dependence conditional on each quantile (Baur, 2013) .", [["QR", "PROTEIN", 99, 101], ["a change in the structure of dependence", "PROBLEM", 50, 89], ["change", "OBSERVATION_MODIFIER", 52, 58], ["dependence", "OBSERVATION_MODIFIER", 79, 89], ["dependence", "OBSERVATION", 178, 188]]], ["It can reveal any type of structure of dependence such as symmetric (e.g. a u-shaped structure or an inverted u-shaped structure) and asymmetric with a left-tail or a right-tail structure of dependence.", [["left-tail", "ANATOMY", 152, 161], ["left-tail", "PROTEIN", 152, 161], ["right-tail structure", "PROTEIN", 167, 187], ["symmetric (e.g. a u-shaped structure", "PROBLEM", 58, 94], ["an inverted u-shaped structure", "PROBLEM", 98, 128], ["a right-tail structure of dependence", "PROBLEM", 165, 201], ["structure", "OBSERVATION", 26, 35], ["dependence", "OBSERVATION", 39, 49], ["symmetric", "OBSERVATION_MODIFIER", 58, 67], ["u-shaped", "OBSERVATION_MODIFIER", 110, 118], ["asymmetric", "OBSERVATION_MODIFIER", 134, 144], ["left", "ANATOMY_MODIFIER", 152, 156], ["tail", "ANATOMY_MODIFIER", 157, 161], ["right", "ANATOMY_MODIFIER", 167, 172], ["tail structure", "OBSERVATION", 173, 187], ["dependence", "OBSERVATION_MODIFIER", 191, 201]]], ["If the estimates are equally high in the tails with lower values in the intermediate quantiles, there is a symmetric u-shaped dependence.", [["the estimates", "TEST", 3, 16], ["a symmetric u-shaped dependence", "PROBLEM", 105, 136], ["equally", "OBSERVATION_MODIFIER", 21, 28], ["high", "OBSERVATION", 29, 33], ["tails", "ANATOMY_MODIFIER", 41, 46], ["lower values", "OBSERVATION_MODIFIER", 52, 64], ["symmetric", "OBSERVATION_MODIFIER", 107, 116], ["u-shaped", "OBSERVATION_MODIFIER", 117, 125], ["dependence", "OBSERVATION", 126, 136]]], ["If the coefficient estimates monotonically increase from the lower quantiles to the upper quantiles, there is an asymmetric dependence structure with a right-tail dependence.", [["right-tail", "ANATOMY", 152, 162], ["an asymmetric dependence structure", "PROBLEM", 110, 144], ["a right-tail dependence", "PROBLEM", 150, 173], ["monotonically", "OBSERVATION_MODIFIER", 29, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["lower", "ANATOMY_MODIFIER", 61, 66], ["upper", "ANATOMY_MODIFIER", 84, 89], ["asymmetric", "OBSERVATION_MODIFIER", 113, 123], ["dependence", "OBSERVATION", 124, 134], ["right", "ANATOMY_MODIFIER", 152, 157], ["tail dependence", "OBSERVATION", 158, 173]]], ["If the coefficient estimates monotonically decrease from the lower quantiles to the upper quantiles, there is an asymmetric dependence structure with a left-tail dependence.", [["an asymmetric dependence structure", "PROBLEM", 110, 144], ["a left-tail dependence", "PROBLEM", 150, 172], ["monotonically", "OBSERVATION_MODIFIER", 29, 42], ["decrease", "OBSERVATION_MODIFIER", 43, 51], ["lower", "ANATOMY_MODIFIER", 61, 66], ["upper", "ANATOMY_MODIFIER", 84, 89], ["asymmetric", "OBSERVATION_MODIFIER", 113, 123], ["dependence", "OBSERVATION", 124, 134], ["left", "ANATOMY_MODIFIER", 152, 156], ["tail dependence", "OBSERVATION", 157, 172]]], ["According to Baur (2013) , there is no need to determine an ad hoc structure for QR since the type of structure is an outcome of the piecewise estimation process of dependence across all quantiles.", [["QR", "PROTEIN", 81, 83]]], ["Therefore, QR offers a more comprehensive picture for any type of structure while accounting for non-linearities and asymmetries.", [["QR", "PROTEIN", 11, 13], ["non-linearities", "PROBLEM", 97, 112], ["asymmetries", "PROBLEM", 117, 128]]], ["A dummy variable (i.e. D COVID ) is used to investigate the degree and structure of dependence in normal times and during the pandemic.", [["A dummy variable (i.e. D COVID )", "TREATMENT", 0, 32], ["dependence", "OBSERVATION_MODIFIER", 84, 94], ["normal", "OBSERVATION", 98, 104]]], ["The test of significance of any type of structural change in any of the quantile is captured by the significance test of and in Equation 1.ResultsThis section presents results of the QR as specified in Eq.", [["QR", "PROTEIN", 183, 185], ["structural change", "PROBLEM", 40, 57]]], ["Table displays the coefficients of , and b which are the main focus of the study.ResultsPanel A reports average coefficient loadings of SP ( ) in Column 2 and an interaction term comprised of SP index and COVID-19 dummy ( ) in Column 4 for selected quantiles (Column 1).", [["SP", "PROTEIN", 136, 138], ["SP", "PROTEIN", 192, 194], ["the study", "TEST", 71, 80], ["SP ( ) in Column", "TREATMENT", 136, 152], ["SP index", "TEST", 192, 200], ["COVID", "TEST", 205, 210], ["main", "OBSERVATION_MODIFIER", 57, 61]]], ["The results show a left-tailed asymmetric dependence structure with differing degree of dependence among SP and industry returns.", [["a left-tailed asymmetric dependence structure", "PROBLEM", 17, 62], ["left", "ANATOMY_MODIFIER", 19, 23], ["tailed", "OBSERVATION_MODIFIER", 24, 30], ["asymmetric", "OBSERVATION_MODIFIER", 31, 41], ["dependence", "OBSERVATION", 42, 52], ["differing", "OBSERVATION_MODIFIER", 68, 77], ["degree", "OBSERVATION_MODIFIER", 78, 84], ["dependence", "OBSERVATION_MODIFIER", 88, 98]]], ["The estimates show an asymmetric dependence that is larger in lower tail (1.024) compared to the upper tail (0.870).", [["upper tail", "ANATOMY", 97, 107], ["upper tail", "ORGANISM_SUBDIVISION", 97, 107], ["an asymmetric dependence", "PROBLEM", 19, 43], ["asymmetric", "OBSERVATION_MODIFIER", 22, 32], ["dependence", "OBSERVATION", 33, 43], ["larger", "OBSERVATION_MODIFIER", 52, 58], ["lower", "ANATOMY_MODIFIER", 62, 67], ["tail", "ANATOMY_MODIFIER", 68, 72], ["upper", "ANATOMY_MODIFIER", 97, 102], ["tail", "ANATOMY_MODIFIER", 103, 107]]], ["The estimates for the COVID effect revel an asymmetric U-shape that can be characterized by right-tail dependence with higher values in tails and lower values around the mid-point.", [["the COVID effect", "PROBLEM", 18, 34], ["an asymmetric U-shape", "PROBLEM", 41, 62], ["right-tail dependence", "PROBLEM", 92, 113], ["higher values in tails", "PROBLEM", 119, 141], ["asymmetric", "OBSERVATION_MODIFIER", 44, 54], ["U-shape", "OBSERVATION_MODIFIER", 55, 62], ["right", "ANATOMY_MODIFIER", 92, 97], ["tail", "ANATOMY_MODIFIER", 98, 102], ["dependence", "OBSERVATION", 103, 113], ["higher", "OBSERVATION_MODIFIER", 119, 125], ["values", "OBSERVATION_MODIFIER", 126, 132], ["tails", "OBSERVATION_MODIFIER", 136, 141], ["lower values", "OBSERVATION_MODIFIER", 146, 158], ["mid-point", "ANATOMY_MODIFIER", 170, 179]]], ["Based on this, the degree of dependence between industry returns and SP considerably increased in higher quantiles for the selected period.ResultsPositive estimates in the right-tail indicate increased co-movement among returns.", [["right-tail", "ANATOMY", 172, 182], ["SP", "PROTEIN", 69, 71], ["SP", "PROBLEM", 69, 71], ["increased co-movement", "PROBLEM", 192, 213], ["dependence", "OBSERVATION", 29, 39], ["considerably", "OBSERVATION_MODIFIER", 72, 84], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["right", "ANATOMY_MODIFIER", 172, 177], ["tail", "ANATOMY_MODIFIER", 178, 182], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["co-movement", "OBSERVATION", 202, 213]]], ["The results show a change in structure of dependence as well due to the asymmetric change in the degree of dependence for some quantiles.", [["a change in structure of dependence", "PROBLEM", 17, 52], ["the asymmetric change", "PROBLEM", 68, 89], ["some quantiles", "PROBLEM", 122, 136], ["change", "OBSERVATION_MODIFIER", 19, 25], ["structure", "OBSERVATION_MODIFIER", 29, 38], ["dependence", "OBSERVATION_MODIFIER", 42, 52], ["asymmetric", "OBSERVATION_MODIFIER", 72, 82], ["change", "OBSERVATION", 83, 89], ["degree", "OBSERVATION_MODIFIER", 97, 103], ["dependence", "OBSERVATION", 107, 117]]], ["The COVID-19 outbreak converted the left-tailed dependence into a right tailed dependence.", [["The COVID", "TEST", 0, 9], ["a right tailed dependence", "PROBLEM", 64, 89], ["left", "ANATOMY_MODIFIER", 36, 40], ["tailed dependence", "OBSERVATION", 41, 58], ["right", "ANATOMY_MODIFIER", 66, 71], ["tailed dependence", "OBSERVATION", 72, 89]]], ["Accordingly, there exist an increased co-movement in the upper quantiles.", [["an increased co-movement in the upper quantiles", "PROBLEM", 25, 72], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["co-movement", "OBSERVATION", 38, 49], ["upper", "ANATOMY_MODIFIER", 57, 62]]], ["This finding is in line with Baur (2013) related to the behavior of stock returns during crisis in emerging markets, degree of dependence increased in upper tail but there is no change in the lower tails.", [["upper tail", "ANATOMY", 151, 161], ["upper tail", "ORGANISM_SUBDIVISION", 151, 161], ["crisis", "PROBLEM", 89, 95], ["dependence increased in upper tail", "PROBLEM", 127, 161], ["change in the lower tails", "PROBLEM", 178, 203], ["degree", "OBSERVATION_MODIFIER", 117, 123], ["dependence", "OBSERVATION_MODIFIER", 127, 137], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["upper", "ANATOMY_MODIFIER", 151, 156], ["tail", "ANATOMY", 157, 161], ["no", "UNCERTAINTY", 175, 177], ["change", "OBSERVATION_MODIFIER", 178, 184], ["lower", "ANATOMY_MODIFIER", 192, 197], ["tails", "ANATOMY_MODIFIER", 198, 203]]], ["The right-tailed asymmetric structure of dependence during outbreak cannot be explained by margin calls, liquidations and wealth constraints which are normally seen as lower tail behavior.ResultsPanel B reports average coefficient loadings of GSIC ( ) in Column 2 and an interaction term comprised of GSIC and COVID-19 dummy (b) in Column 4.", [["tail", "ANATOMY", 174, 178], ["tail", "ORGANISM_SUBDIVISION", 174, 178], ["GSIC", "PROTEIN", 243, 247], ["COVID", "PROTEIN", 310, 315], ["GSIC ( ) in Column 2", "PROBLEM", 243, 263], ["GSIC", "TEST", 301, 305], ["COVID", "TEST", 310, 315], ["right", "ANATOMY_MODIFIER", 4, 9], ["tailed", "OBSERVATION_MODIFIER", 10, 16], ["asymmetric", "OBSERVATION_MODIFIER", 17, 27], ["structure", "OBSERVATION_MODIFIER", 28, 37], ["dependence", "OBSERVATION_MODIFIER", 41, 51], ["cannot be explained", "UNCERTAINTY", 68, 87], ["lower tail", "OBSERVATION_MODIFIER", 168, 178], ["Column", "ANATOMY", 332, 338]]], ["The results show an S-shaped asymmetric dependence structure that is negative and stronger in the lower quantiles and positive and relatively weaker in the higher quantiles.", [["an S-shaped asymmetric dependence structure", "PROBLEM", 17, 60], ["S-shaped", "OBSERVATION_MODIFIER", 20, 28], ["asymmetric", "OBSERVATION_MODIFIER", 29, 39], ["dependence structure", "OBSERVATION", 40, 60], ["negative", "OBSERVATION", 69, 77], ["stronger", "OBSERVATION_MODIFIER", 82, 90], ["positive", "OBSERVATION", 118, 126], ["relatively", "OBSERVATION_MODIFIER", 131, 141], ["weaker", "OBSERVATION_MODIFIER", 142, 148]]], ["These patterns indicate tail dependence in returns-GSIC relationship that is stronger in the left-tail.", [["tail", "ANATOMY", 24, 28], ["left-tail", "ANATOMY", 93, 102], ["tail", "ORGANISM_SUBDIVISION", 24, 28], ["left-tail", "PROTEIN", 93, 102], ["tail dependence", "PROBLEM", 24, 39], ["tail dependence", "OBSERVATION", 24, 39], ["stronger", "OBSERVATION_MODIFIER", 77, 85], ["left", "ANATOMY_MODIFIER", 93, 97], ["tail", "ANATOMY", 98, 102]]], ["The median estimation is -0.005 and insignificant, justifying prior predictions of the paper about linear dependence models.", [["The median estimation", "TEST", 0, 21], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["Overall, increased attention towards coronavirus has negative and higher effects on industries in the lower tail of distribution but positive and lower effects on industries in the upper tail of distribution.", [["coronavirus", "ORGANISM", 37, 48], ["upper tail", "ORGANISM_SUBDIVISION", 181, 191], ["coronavirus", "PROBLEM", 37, 48], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["higher effects", "OBSERVATION_MODIFIER", 66, 80], ["lower tail", "ANATOMY_MODIFIER", 102, 112], ["positive", "OBSERVATION", 133, 141], ["lower effects", "OBSERVATION_MODIFIER", 146, 159], ["upper tail", "ANATOMY_MODIFIER", 181, 191]]], ["The estimates for is only significant at 97.5% quantiles.", [["The estimates", "TEST", 0, 13]]], ["Accordingly, except for the highest tail, the interaction term of GSIC-DCOVID cannot affect the degree and structure of dependence between GSIC and industry returns.", [["GSIC", "PROTEIN", 66, 70], ["GSIC-DCOVID", "TREATMENT", 66, 77]]], ["The vertical axis in each graph represents dependence measured by parameter estimates and horizontal axis represents quantiles.ConclusionThis study uses a QR approach to measure the impact of COVID-19 on the dependence of industry returns and the structure of the risk-return relationship.", [["This study", "TEST", 137, 147], ["a QR approach", "TREATMENT", 153, 166], ["COVID", "TEST", 192, 197], ["vertical axis", "OBSERVATION", 4, 17], ["dependence", "OBSERVATION", 43, 53], ["horizontal axis", "OBSERVATION", 90, 105]]], ["Overall, results indicate a left-tailed asymmetric dependence structure of industry returns with market portfolio in normal times.", [["a left-tailed asymmetric dependence structure", "PROBLEM", 26, 71], ["left", "ANATOMY_MODIFIER", 28, 32], ["asymmetric", "OBSERVATION_MODIFIER", 40, 50], ["dependence", "OBSERVATION", 51, 61], ["industry", "OBSERVATION_MODIFIER", 75, 83], ["market", "OBSERVATION_MODIFIER", 97, 103], ["portfolio", "OBSERVATION_MODIFIER", 104, 113], ["normal times", "OBSERVATION_MODIFIER", 117, 129]]], ["Following the COVID-19 outbreak, degree of dependence between returns and market portfolio has increased in the higher quantiles, lowering the benefits of diversification.", [["the COVID", "TEST", 10, 19], ["dependence", "OBSERVATION_MODIFIER", 43, 53], ["increased", "OBSERVATION_MODIFIER", 95, 104]]], ["The COVID-19 outbreak also converted the left-tailed dependence into a right tailed dependence, indicating a shift in the structure of risk-return relationship.", [["The COVID", "TEST", 0, 9], ["a right tailed dependence", "PROBLEM", 69, 94], ["a shift", "PROBLEM", 107, 114], ["left", "ANATOMY_MODIFIER", 41, 45], ["tailed dependence", "OBSERVATION_MODIFIER", 46, 63], ["right", "ANATOMY_MODIFIER", 71, 76], ["tailed dependence", "OBSERVATION", 77, 94], ["shift", "OBSERVATION", 109, 114]]], ["In addition, the GSIC-return relationship revealed an asymmetric pattern, lower tails influenced negatively and almost twice as much compared to the upper tails which influenced positively from increased search activity.", [["GSIC", "GENE_OR_GENE_PRODUCT", 17, 21], ["GSIC", "PROTEIN", 17, 21], ["the GSIC", "TEST", 13, 21], ["an asymmetric pattern", "PROBLEM", 51, 72], ["increased search activity", "PROBLEM", 194, 219], ["asymmetric pattern", "OBSERVATION", 54, 72], ["lower tails", "ANATOMY", 74, 85], ["upper tails", "ANATOMY", 149, 160], ["increased", "OBSERVATION_MODIFIER", 194, 203], ["search activity", "OBSERVATION", 204, 219]]], ["Except for the highest tail, the COVID-19 outbreak cannot influence the degree or structure of this S-shaped return-GSIC dependence.", [["the COVID", "TEST", 29, 38], ["this S-shaped return-GSIC dependence", "PROBLEM", 95, 131], ["highest tail", "ANATOMY", 15, 27], ["shaped", "OBSERVATION_MODIFIER", 102, 108], ["return-GSIC dependence", "OBSERVATION", 109, 131]]], ["First, market reaction to COVID-19 in terms of change in dependence and structure of risk-return relationship follows a contagion like patterns and show similarities to that of 2008 crisis documented by prior literature.", [["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "DNA", 26, 34], ["COVID", "TEST", 26, 31], ["change in dependence", "PROBLEM", 47, 67]]], ["This relationship is not significant on and around median.", [["not", "UNCERTAINTY", 21, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["The asymmetric dependence could be related to investors' risk aversion behavior around catastrophe events.", [["The asymmetric dependence", "PROBLEM", 0, 25], ["catastrophe events", "PROBLEM", 87, 105], ["asymmetric", "OBSERVATION_MODIFIER", 4, 14], ["dependence", "OBSERVATION", 15, 25]]]], "PMC7126023": [], "PMC7493832": [["Impact on clinical trial operations ::: IntroductionDisruptions due to disaster can often result in disruptions to study protocols, challenges to data interpretation, the need for Institutional Review Board (IRB) amendments, and the introduction of new biases [2].", [["study protocols", "TEST", 115, 130]]], ["Prior research highlights the importance of proactive plans to minimize study disruption, the need to adapt rapidly to changing constraints, and the importance of ongoing communication with contract research organizations and sponsors and to share and develop strategies to mitigate participant-related protocol deviations and violations.", [["proactive plans", "TREATMENT", 44, 59], ["study disruption", "PROBLEM", 72, 88]]], ["Application of these actions should all occur in the context of local conditions.Impact on clinical trial operations ::: IntroductionResearchers have not previously seen this global level of disruption to clinical trials.", [["these actions", "TREATMENT", 15, 28]]], ["Effects of COVID-19 on geriatric clinical trials research will be long-lasting.", [["COVID-19", "CHEMICAL", 11, 19], ["COVID-19", "CHEMICAL", 11, 19], ["COVID", "TEST", 11, 16], ["geriatric clinical trials", "TREATMENT", 23, 48]]], ["Trials in their enrollment phase will at a minimum be delayed in achieving full recruitment, leading to lags in, or losses of, discovery.", [["recruitment", "OBSERVATION", 80, 91]]], ["Depending on the duration of stay-at-home orders, some studies may be permanently disrupted and discontinued.", [["some studies", "TEST", 50, 62]]], ["For more established trials, if attrition leads to final sample sizes much smaller than those required by the a priori power estimates, then these ongoing studies may not have enough statistical power to identify positive findings.", [["these ongoing studies", "TEST", 141, 162], ["positive findings", "PROBLEM", 213, 230]]], ["Trials that involve in-person cognitive assessment face challenges as they move to other modalities for testing, which may influence results.", [["cognitive assessment", "TEST", 30, 50], ["testing", "TEST", 104, 111]]], ["Efforts to validate existing measures through remote assessment should continue, to enable meaningful cognitive measures to be assessed remotely.", [["remote assessment", "TEST", 46, 63], ["meaningful cognitive measures", "TREATMENT", 91, 120]]], ["In addition, investment in low cost technology to support these efforts, for participants who may not have remote access, may enable studies to continue with limited disruption, while also ensuring those of lower socioeconomic status are not left behind.Impact on participant safety and engagement ::: IntroductionClinical trials involving those with cognitive impairment face unique challenges during such crises [1].", [["cognitive impairment", "DISEASE", 351, 371], ["participants", "SPECIES", 77, 89], ["limited disruption", "PROBLEM", 158, 176], ["IntroductionClinical trials", "TREATMENT", 302, 329], ["cognitive impairment", "PROBLEM", 351, 371], ["left", "ANATOMY_MODIFIER", 242, 246]]], ["At a time of social distancing, routines and support systems are dramatically altered.", [["dramatically altered", "PROBLEM", 65, 85]]], ["Social cohesion and community can offer protections and resiliency for older adults during the time of disaster management.", [["disaster management", "TREATMENT", 103, 122]]], ["Maintaining and supporting active participant and recruitment engagement is essential.", [["active", "OBSERVATION_MODIFIER", 27, 33]]], ["Many of the existing safety and efficacy measures within current trials are coming to a halt or being offered through non-traditional means, with unknown validity.", [["efficacy measures", "TREATMENT", 32, 49], ["current trials", "TREATMENT", 57, 71]]], ["Individuals continuing to take experimental medications may continue to have check-in safety calls but may have delays in bloodwork and imaging scans that would otherwise provide reassurance regarding any potential adverse medication effects.", [["experimental medications", "TREATMENT", 31, 55], ["imaging scans", "TEST", 136, 149], ["reassurance", "TREATMENT", 179, 190], ["any potential adverse medication effects", "PROBLEM", 201, 241]]], ["For infusion studies, medication delivery may be halted, but lingering effects of existing dosages are still possible.", [["infusion studies", "TEST", 4, 20], ["medication delivery", "TREATMENT", 22, 41], ["existing dosages", "TREATMENT", 82, 98]]], ["Careful evaluation of potential drug effects and critical safety measures will optimize the likelihood that safety is not compromised.", [["Careful evaluation", "TEST", 0, 18], ["potential drug effects", "PROBLEM", 22, 44], ["critical safety measures", "TREATMENT", 49, 73], ["drug effects", "OBSERVATION", 32, 44]]], ["Behavioral studies have additional challenges due to the prolonged proximity of participants and researchers required in some intervention.", [["participants", "SPECIES", 80, 92], ["Behavioral studies", "TEST", 0, 18], ["some intervention", "TREATMENT", 121, 138]]], ["While the impact of abrupt halting of these trials is yet to be known, maintaining vigilance while planning to resume is essential.", [["these trials", "TREATMENT", 38, 50], ["abrupt", "OBSERVATION_MODIFIER", 20, 26]]], ["There is need for attention to implement gradual, careful restart processes that aim to keep participants safe while minimizing disruption to trials.", [["participants", "SPECIES", 93, 105], ["careful restart processes", "TREATMENT", 50, 75]]], ["These measures will maximize existing contributions and ensure the success of ongoing trials.Impact on participant safety and engagement ::: IntroductionAssessing efficacy will be more complex, as the evaluation will necessitate consideration of history effects within studies including the upheaval to daily routines and changes in cognitive and social stimulation that COVID-19 has created.", [["ongoing trials", "TREATMENT", 78, 92], ["the evaluation", "TEST", 197, 211], ["the upheaval to daily routines", "TREATMENT", 287, 317], ["cognitive and social stimulation", "TREATMENT", 333, 365], ["COVID", "TEST", 371, 376]]], ["Methodological counterpoints will need to be considered including the role of randomization in distributing the psychosocial effects across groups, the timing of enrollment within the pandemic onset, and testing or controlling for psychological sequelae of COVID-19, such as controlling for depressive symptoms or the impact of social isolation and loneliness.", [["depressive symptoms", "DISEASE", 291, 310], ["loneliness", "DISEASE", 349, 359], ["Methodological counterpoints", "TREATMENT", 0, 28], ["randomization", "TREATMENT", 78, 91], ["testing", "TEST", 204, 211], ["COVID", "TREATMENT", 257, 262], ["depressive symptoms", "PROBLEM", 291, 310], ["social isolation", "TREATMENT", 328, 344]]], ["Further, as noted above, changing test administration from in-person to digital modalities that can be conducted remotely out of the office will introduce additional variability into efficacy assessments.Disparate impact by age, race, and ethnicity ::: IntroductionIn the US, morbidity and mortality early in the COVID-19 pandemic has disproportionately affected older adults and Black/African-American and Hispanic-American communities [3].", [["changing test administration", "TREATMENT", 25, 53], ["efficacy assessments", "TEST", 183, 203], ["the US", "TEST", 268, 274], ["morbidity", "PROBLEM", 276, 285]]], ["Existing barriers to engaging hard to reach participants will likely be exacerbated.", [["participants", "SPECIES", 44, 56]]], ["We must make concerted efforts in recruitment and retention to ensure advancements we have made in regard to increasing the representative population sample engaged in clinical trial research are sustained.Impact on biomarker outcomes ::: IntroductionRecent past and anticipated future successes in clinical trial activity in the area of aging and dementia have relied on biomarker assessments including: brain imaging (MRI, PET and other), which requires shared and repetitive usage of common acquisition facilities; retinal imaging and EEG, which require the use of shared equipment that may be difficult to sterilize or sanitize between participants.", [["brain", "ANATOMY", 405, 410], ["retinal", "ANATOMY", 518, 525], ["dementia", "DISEASE", 348, 356], ["brain", "ORGAN", 405, 410], ["retinal", "MULTI-TISSUE_STRUCTURE", 518, 525], ["participants", "SPECIES", 640, 652], ["clinical trial activity", "TREATMENT", 299, 322], ["dementia", "PROBLEM", 348, 356], ["biomarker assessments", "TEST", 372, 393], ["brain imaging", "TEST", 405, 418], ["MRI", "TEST", 420, 423], ["retinal imaging", "TEST", 518, 533], ["EEG", "TEST", 538, 541], ["shared equipment", "TREATMENT", 568, 584], ["dementia", "OBSERVATION", 348, 356], ["retinal", "ANATOMY", 518, 525]]], ["Discovery of disease-modifying therapies in the area of dementia research, especially preclinical dementia, is dependent on such measures.", [["dementia", "DISEASE", 56, 64], ["dementia", "DISEASE", 98, 106], ["disease", "PROBLEM", 13, 20], ["modifying therapies", "TREATMENT", 21, 40], ["dementia", "PROBLEM", 56, 64], ["preclinical dementia", "PROBLEM", 86, 106], ["such measures", "TREATMENT", 124, 137], ["disease", "OBSERVATION", 13, 20], ["dementia", "OBSERVATION", 56, 64], ["dependent", "OBSERVATION_MODIFIER", 111, 120]]], ["Coordination of using shared medical facilities such as imaging equipment including MRI and PET scanners for continued conduct has been a challenge due to concerns of COVID-19 transmission, despite the critical need for the acquisition of essential imaging and safety information mandated by participant status and clinical trial conduct.", [["imaging equipment", "TEST", 56, 73], ["MRI", "TEST", 84, 87], ["PET scanners", "TEST", 92, 104], ["COVID", "TEST", 167, 172], ["essential imaging", "TEST", 239, 256], ["clinical trial conduct", "TEST", 315, 337]]], ["Development of specific and diligent methods to sterilize, sanitize, and convey these safety precautions to the public will allow continued engagement in clinical research activities.Impact on clinical trials workforce ::: IntroductionAs with prior disasters, many research sites in the US have been forced to shut down and/or limit activities as a result of local or state restrictions due to COVID-19.", [["sanitize", "TREATMENT", 59, 67], ["these safety precautions", "TREATMENT", 80, 104], ["prior disasters", "TREATMENT", 243, 258], ["COVID", "TEST", 394, 399]]], ["Thus, critical research activity that supports the financial infrastructure of these research sites may be diminished and/or completely disappear.", [["diminished", "PROBLEM", 107, 117], ["diminished", "OBSERVATION", 107, 117]]], ["It may not be possible for some investigators to continue to provide salary support for their well-trained research staff members, not only leading to dissolution of the existing research site infrastructure but also contributing further to the ongoing societal burden of the COVID-19 crisis.", [["salary support", "TREATMENT", 69, 83], ["the COVID", "TEST", 272, 281], ["may not be possible", "UNCERTAINTY", 3, 22]]], ["Such impact may also impede advancement of researchers\u2019 careers.Impact on clinical trials workforce ::: IntroductionThe need for the cultivation and maintenance of a workforce trained for enhancing older adults\u2019 engagement in clinical trial activities has been overlooked for years.", [["the cultivation", "TREATMENT", 129, 144], ["a workforce trained", "TREATMENT", 164, 183]]], ["Developing such skill sets and desires to work in research may be severely limited by the COVID-19 crisis unless we are able to ensure stability of the underlying research infrastructure.", [["the COVID-19 crisis", "PROBLEM", 86, 105]]], ["The call for advocacy is needed for sustained funding mechanisms that offer emergency support and stable institutional standing to ensure continuity and protection of these positions.Immediate and future funding allocation ::: IntroductionGiven the heightened public interest in advancing scientific and medical initiatives to combat the COVID-19 crisis, as well as the financial burden the crisis is posing globally, there is increasing competition for resources that have long been lacking in the field.", [["emergency support", "TREATMENT", 76, 93], ["medical initiatives", "TREATMENT", 304, 323], ["the COVID", "TREATMENT", 334, 343]]], ["Funding increases for aging-related research were moving at a rapid pace but funds now may be in jeopardy with this competing need.", [["a rapid pace", "TREATMENT", 60, 72]]], ["Large-scale funding from the NIH is being redirected to directly combat the COVID-19 pandemic.", [["the COVID", "TEST", 72, 81], ["pandemic", "PROBLEM", 85, 93], ["-scale", "OBSERVATION_MODIFIER", 5, 11]]], ["While immediate repercussions on the budget for National Institute on Aging has not yet occurred, we hope that specific aging-related research continues to receive the funds necessary to move the field forward.", [["the funds", "TREATMENT", 164, 173]]], ["Representation and advocacy for aging science by stakeholders is imperative to protect current availability of geriatric clinical trial research.Impact on future research ::: IntroductionAs scientists consider lasting implications of COVID-19, future study design planning and management will likely be altered.", [["geriatric clinical trial research", "TREATMENT", 111, 144], ["COVID", "TEST", 234, 239], ["management", "TREATMENT", 277, 287]]], ["Specifically, increased utilization of participant-centered design while maintaining rigor and reproducibility is crucial.", [["increased", "OBSERVATION_MODIFIER", 14, 23]]], ["Study design that promotes engagement in a way that meets older adults\u2019 unique needs with enhanced ease in access will be needed.", [["enhanced ease in access", "TREATMENT", 90, 113]]], ["Current and ongoing recruitment avenues and disaster preparedness plans must acknowledge ways to mitigate decreased contact with older participants who do not use email or computers.", [["participants", "SPECIES", 135, 147], ["disaster preparedness", "TREATMENT", 44, 65]]], ["Further, care for participants that typically occurs during clinical trials under the supervision of medical professionals will need to be adjusted to maintain safety.Impact on future research ::: IntroductionDevelopment, maintenance, and implementation of disaster and business continuity plans within clinical trial design is needed in future planning.", [["participants", "SPECIES", 18, 30], ["medical professionals", "TREATMENT", 101, 122]]], ["Mische and Wilkerson [5] describe the need for preparation using risk analyses, response during disasters with implementation of essential functions, recovery efforts, and mitigation of losses to clinical trial data and resources.", [["risk analyses", "TEST", 65, 78], ["clinical trial data", "TEST", 196, 215]]], ["Clinical trial continuity for interventions and care of older adults, especially those with cognitive impairment, is paramount.", [["cognitive impairment", "DISEASE", 92, 112], ["Clinical trial continuity", "TREATMENT", 0, 25], ["interventions", "TREATMENT", 30, 43], ["cognitive impairment", "PROBLEM", 92, 112]]], ["The vulnerability of older adults to COVID-19 is a critical reminder for the need to prepare for disasters during clinical trial design.Impact on future research ::: IntroductionFuture changes in regulatory and industry perspectives on trial conduct could be profound.", [["COVID-19", "CHEMICAL", 37, 45], ["IntroductionFuture changes", "PROBLEM", 166, 192]]], ["New trial design methodologies will need to be developed to take into account significant periods of time for subpopulation and/or total population of subjects that may not be able to conduct regular research activities.", [["New trial design methodologies", "TREATMENT", 0, 30]]], ["Our patient population regularly encounters unexpected healthcare, social, and/or personal crises that are considered significant disruptions to smooth research conduct.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["significant disruptions", "PROBLEM", 118, 141], ["smooth", "OBSERVATION_MODIFIER", 145, 151]]], ["The potential for increasing recognition of such confounds in interpreting clinical trial data could help to smooth regulatory pathways for studies that encounter such obstacles in the future.ConclusionScientists face unprecedented challenges with long-lasting impacts due to COVID-19.", [["COVID-19", "DNA", 276, 284], ["such confounds", "PROBLEM", 44, 58], ["COVID", "TEST", 276, 281]]], ["By learning from prior disasters and epidemics, we can be prepared to address current and upcoming changes.", [["epidemics", "PROBLEM", 37, 46]]], ["Increased acknowledgement of a variety of social determinants of health will allow improved efforts to ensure innovative analytic approaches, as well as structures to support the research workforce and opportunities that keep research dissemination and scientific discovery active and productive.", [["innovative analytic approaches", "TREATMENT", 110, 140]]]], "6113941ae73e1bba115d8f7d5f23d148ee3120fe": [["INTRODUCTIONOn December 2019, the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 (formerly known as 2019-nCov) 1 was found in pneumonia patients in Wuhan, China.", [["acute respiratory syndrome coronavirus", "DISEASE", 41, 79], ["pneumonia", "DISEASE", 139, 148], ["SARS-CoV-2", "ORGANISM", 83, 93], ["Cov) 1", "GENE_OR_GENE_PRODUCT", 119, 125], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["severe acute respiratory syndrome coronavirus", "SPECIES", 34, 79], ["SARS-CoV", "SPECIES", 83, 91], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 30, 79], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["pneumonia", "PROBLEM", 139, 148], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory syndrome", "OBSERVATION", 47, 67], ["pneumonia", "OBSERVATION", 139, 148]]], ["This virus is responsible for a life-threatening respiratory coronavirus disease 2019 .", [["respiratory coronavirus disease", "DISEASE", 49, 80], ["This virus", "PROBLEM", 0, 10], ["a life-threatening respiratory coronavirus disease", "PROBLEM", 30, 80], ["responsible for", "UNCERTAINTY", 14, 29], ["respiratory coronavirus disease", "OBSERVATION", 49, 80]]], ["2 This virus then quickly spread to most continents around the globe.", [["globe", "ORGAN", 63, 68], ["This virus", "PROBLEM", 2, 12], ["globe", "ANATOMY", 63, 68]]], ["The death rates vary in different countries, but all of them tend to be on the high side compared with many respiratory infectious diseases.", [["death", "DISEASE", 4, 9], ["respiratory infectious diseases", "DISEASE", 108, 139], ["The death rates", "PROBLEM", 0, 15], ["many respiratory infectious diseases", "PROBLEM", 103, 139], ["respiratory", "ANATOMY", 108, 119], ["infectious", "OBSERVATION", 120, 130]]], ["Elder persons have higher risks of mortality.", [["persons", "ORGANISM", 6, 13], ["persons", "SPECIES", 6, 13]]], ["3 As of April 2020, SARS-CoV-2 is still plaguing most countries in the world, with a total death count of more than 45 000 people.", [["SARS", "DISEASE", 20, 24], ["death", "DISEASE", 91, 96], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129], ["SARS-CoV", "SPECIES", 20, 28], ["a total death count", "TEST", 83, 102]]], ["On the other hand, many infected patients have very mild symptoms or remain completely asymptomatic during the entire course of infection.", [["infection", "DISEASE", 128, 137], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["very mild symptoms", "PROBLEM", 47, 65], ["completely asymptomatic", "PROBLEM", 76, 99], ["infection", "PROBLEM", 128, 137], ["infected", "OBSERVATION", 24, 32], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["infection", "OBSERVATION", 128, 137]]], ["The occult infections represent a major threat to public health because infected persons with mild symptoms could still transmit the disease to other people.", [["occult infections", "DISEASE", 4, 21], ["persons", "ORGANISM", 81, 88], ["people", "ORGANISM", 150, 156], ["persons", "SPECIES", 81, 88], ["people", "SPECIES", 150, 156], ["The occult infections", "PROBLEM", 0, 21], ["mild symptoms", "PROBLEM", 94, 107], ["the disease", "PROBLEM", 129, 140], ["occult", "OBSERVATION_MODIFIER", 4, 10], ["infections", "OBSERVATION", 11, 21], ["mild", "OBSERVATION_MODIFIER", 94, 98]]], ["Reliable biosensor systems for the detection of this virus with high sensitivity and specificity are therefore in urgent demand for the control of the SARS-CoV-2 pandemic.INTRODUCTIONSARS-CoV-2 is a positive-sense, single-stranded RNA virus.", [["SARS-CoV-2 pandemic", "DISEASE", 151, 170], ["SARS-CoV-2", "ORGANISM", 151, 161], ["INTRODUCTIONSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 171, 193], ["CoV-2", "DNA", 188, 193], ["SARS-CoV", "SPECIES", 151, 159], ["this virus", "PROBLEM", 48, 58], ["high sensitivity", "PROBLEM", 64, 80], ["urgent demand", "TREATMENT", 114, 127], ["the SARS", "PROBLEM", 147, 155], ["CoV", "TEST", 156, 159], ["pandemic", "PROBLEM", 162, 170], ["INTRODUCTIONSARS", "TEST", 171, 187], ["CoV", "TEST", 188, 191], ["single-stranded RNA virus", "PROBLEM", 215, 240], ["RNA virus", "OBSERVATION", 231, 240]]], ["The SARS-CoV-2 genome encodes nucleocapsid (N), spike (S), envelope (E), and membrane (M) proteins, where S, E, and M are components of the viral envelope.", [["membrane", "ANATOMY", 77, 85], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 30, 46], ["spike (S)", "GENE_OR_GENE_PRODUCT", 48, 57], ["E", "GENE_OR_GENE_PRODUCT", 69, 70], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["S, E", "GENE_OR_GENE_PRODUCT", 106, 110], ["SARS-CoV-2 genome", "DNA", 4, 21], ["nucleocapsid (N), spike (S), envelope (E), and membrane (M) proteins", "PROTEIN", 30, 98], ["S, E, and M", "PROTEIN", 106, 117], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["spike (S), envelope (E), and membrane (M) proteins", "PROBLEM", 48, 98], ["the viral envelope", "PROBLEM", 136, 154], ["viral envelope", "OBSERVATION", 140, 154]]], ["It also encodes nonstructural genes of open reading frames 1a, 1b, 3, 6, 7a, 8, and 10.", [["open reading frames 1a", "GENE_OR_GENE_PRODUCT", 39, 61], ["3", "GENE_OR_GENE_PRODUCT", 67, 68], ["7a", "GENE_OR_GENE_PRODUCT", 73, 75], ["8", "GENE_OR_GENE_PRODUCT", 77, 78], ["10", "GENE_OR_GENE_PRODUCT", 84, 86], ["nonstructural genes", "DNA", 16, 35], ["open reading frames 1a, 1b, 3, 6, 7a, 8, and 10", "DNA", 39, 86], ["nonstructural genes", "OBSERVATION", 16, 35]]], ["Similar infection routes and life cycles were found between SARS-CoV-2 and SARS-CoV-1, the virus that caused the Asian Abstract: The recent outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been causing respiratory diseases globally, damaging wide ranges of social-economic activities.", [["respiratory", "ANATOMY", 243, 254], ["infection", "DISEASE", 8, 17], ["acute respiratory syndrome coronavirus", "DISEASE", 163, 201], ["SARS-CoV-2) pandemic", "DISEASE", 205, 225], ["respiratory diseases", "DISEASE", 243, 263], ["SARS-CoV-2", "ORGANISM", 60, 70], ["SARS-CoV-1", "ORGANISM", 75, 85], ["SARS-CoV-2", "ORGANISM", 205, 215], ["CoV-1", "SPECIES", 80, 85], ["CoV-2", "SPECIES", 210, 215], ["SARS-CoV", "SPECIES", 60, 68], ["SARS-CoV-1", "SPECIES", 75, 85], ["severe acute respiratory syndrome coronavirus", "SPECIES", 156, 201], ["SARS-CoV-2", "SPECIES", 205, 215], ["Similar infection routes", "PROBLEM", 0, 24], ["life cycles", "TEST", 29, 40], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["the virus", "PROBLEM", 87, 96], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 152, 201], ["pandemic", "PROBLEM", 217, 225], ["respiratory diseases", "PROBLEM", 243, 263], ["infection", "OBSERVATION", 8, 17], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory syndrome", "OBSERVATION", 169, 189], ["respiratory diseases", "OBSERVATION", 243, 263], ["wide", "OBSERVATION_MODIFIER", 283, 287], ["ranges", "OBSERVATION_MODIFIER", 288, 294]]], ["This virus is transmitted through personal contact and possibly also through ambient air.", [["virus", "OBSERVATION", 5, 10]]], ["Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand.", [["this virus", "PROBLEM", 51, 61], ["host response", "OBSERVATION", 78, 91]]], ["These platforms can facilitate routine diagnostic assays in certified clinical laboratories.", [["routine diagnostic assays", "TEST", 31, 56]]], ["They can also be integrated into point-of-care products.", [["care products", "TREATMENT", 42, 55]]], ["Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators.", [["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["the intensive care ventilators", "TREATMENT", 100, 130]]], ["Effective SARS-CoV-2 detectors can be designed by an adequate combination of these technologies.INTRODUCTIONKeywords: Aerosol; Coronavirus disease 2019; Fluorescence resonance energy transfer-based biosensors; Protein-protein interactions; Real-time reverse transcription polymerase chain reaction/qPCR; Severe acute respiratory syndrome coronavirus 2/2019-nCov coronavirus endemic in 2003.", [["Coronavirus disease", "DISEASE", 127, 146], ["acute respiratory syndrome coronavirus", "DISEASE", 311, 349], ["Cov coronavirus", "ORGANISM", 358, 373], ["Severe acute respiratory syndrome coronavirus 2/2019-nCov coronavirus", "SPECIES", 304, 373], ["these technologies", "TREATMENT", 77, 95], ["Coronavirus disease", "PROBLEM", 127, 146], ["Fluorescence resonance energy", "TEST", 153, 182], ["based biosensors", "TEST", 192, 208], ["Protein", "TEST", 210, 217], ["chain reaction", "TEST", 283, 297], ["qPCR", "TEST", 298, 302], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 304, 349], ["Cov coronavirus endemic", "PROBLEM", 358, 381], ["Coronavirus disease", "OBSERVATION", 127, 146], ["Severe", "OBSERVATION_MODIFIER", 304, 310], ["acute", "OBSERVATION_MODIFIER", 311, 316], ["respiratory syndrome", "OBSERVATION", 317, 337]]], ["SARS-CoV-2 enters the human cells through the binding of the spike protein and the viral receptor, the angiotensin-converting enzyme 2 (ACE2), triggering endocytosis.", [["cells", "ANATOMY", 28, 33], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 103, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 22, 27], ["cells", "CELL", 28, 33], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 103, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 136, 140], ["human cells", "CELL_TYPE", 22, 33], ["spike protein", "PROTEIN", 61, 74], ["viral receptor", "PROTEIN", 83, 97], ["angiotensin-converting enzyme 2", "PROTEIN", 103, 134], ["ACE2", "PROTEIN", 136, 140], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["SARS-CoV", "TEST", 0, 8], ["the human cells", "TREATMENT", 18, 33], ["the spike protein", "PROBLEM", 57, 74], ["the viral receptor", "TEST", 79, 97], ["the angiotensin", "TEST", 99, 114], ["converting enzyme", "TEST", 115, 132], ["triggering endocytosis", "PROBLEM", 143, 165]]], ["ACE2 are expressed in human cells including the type 2 alveolar cells.", [["cells", "ANATOMY", 28, 33], ["type 2 alveolar cells", "ANATOMY", 48, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 22, 27], ["cells", "CELL", 28, 33], ["type 2 alveolar cells", "CELL", 48, 69], ["ACE2", "PROTEIN", 0, 4], ["human cells", "CELL_TYPE", 22, 33], ["type 2 alveolar cells", "CELL_TYPE", 48, 69], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["ACE2", "TREATMENT", 0, 4], ["human cells", "OBSERVATION", 22, 33], ["alveolar cells", "OBSERVATION", 55, 69]]], ["4 The size of viral particle is 70-90 nm.", [["viral particle", "TEST", 14, 28], ["size", "OBSERVATION_MODIFIER", 6, 10], ["viral particle", "OBSERVATION", 14, 28]]], ["5 Experimental data suggest that this virus is possibly airborne and take advantage of aerosol transmission.", [["this virus", "PROBLEM", 33, 43], ["aerosol transmission", "TREATMENT", 87, 107]]], ["7 In the environment, the virus can stay viable on the surface of plastics and stainless steels for several days.", [["surface", "ANATOMY", 55, 62], ["the virus", "PROBLEM", 22, 31], ["plastics and stainless steels", "TREATMENT", 66, 95], ["virus", "OBSERVATION", 26, 31], ["stainless steels", "OBSERVATION", 79, 95]]], ["6 Designs of a biosensor platforms for the detection of SARS-CoV-2 involve three essential aspects (1) the target of recognition, such as viral RNA, viral proteins, or human immunoglobulins;INTRODUCTION(2) the recognition method, such as via nucleic acid probes, aptamers, antibodies, receptors, where the antibody-antigen binding or receptor-ligand interaction can be detected via the conformational changes of sensor proteins.", [["SARS", "DISEASE", 56, 60], ["nucleic acid", "CHEMICAL", 242, 254], ["SARS-CoV-2", "ORGANISM", 56, 66], ["human", "ORGANISM", 168, 173], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 174, 189], ["antibody-antigen", "GENE_OR_GENE_PRODUCT", 306, 322], ["viral RNA", "RNA", 138, 147], ["viral proteins", "PROTEIN", 149, 163], ["human immunoglobulins", "PROTEIN", 168, 189], ["antibodies", "PROTEIN", 273, 283], ["sensor proteins", "PROTEIN", 412, 427], ["human", "SPECIES", 168, 173], ["SARS-CoV", "SPECIES", 56, 64], ["human", "SPECIES", 168, 173], ["a biosensor platforms", "TEST", 13, 34], ["the detection", "TEST", 39, 52], ["SARS", "PROBLEM", 56, 60], ["CoV", "TEST", 61, 64], ["viral RNA, viral proteins", "PROBLEM", 138, 163], ["nucleic acid probes", "TREATMENT", 242, 261], ["the antibody", "TEST", 302, 314], ["sensor proteins", "PROBLEM", 412, 427]]], ["Enzymatic reactions represent one additional methods of recognition, such as the detection of proteolytic cleavage by specific protease; and (3) the signal amplification and transduction system, for example, electrochemical, electrical, optical, surface plasmon resonance, fluorescent signals, and mechanical systems.", [["protease", "PROTEIN", 127, 135], ["Enzymatic reactions", "PROBLEM", 0, 19], ["proteolytic cleavage", "PROBLEM", 94, 114], ["the signal amplification", "TEST", 145, 169], ["surface plasmon resonance", "TEST", 246, 271], ["fluorescent signals", "TEST", 273, 292]]], ["For environmental applications, samplers need to be incorporated for handling samples directly from the environment.", [["samples", "ANATOMY", 78, 85], ["environmental applications", "TREATMENT", 4, 30], ["samplers", "TREATMENT", 32, 40]]], ["For example, if the samples were to be taken from the ambient air, then air samplers were needed to be designed.", [["samples", "ANATOMY", 20, 27], ["the samples", "TEST", 16, 27], ["air samplers", "TREATMENT", 72, 84]]], ["9 Here, we review biosensor technologies which may be utilized for the development of clinically useful SARS-CoV-2 detection platforms.TARGETS OF RECOGNITIONThe viral RNA, viral proteins, or human immunoglobulin could all be the targets of recognition.", [["human", "ORGANISM", 191, 196], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 197, 211], ["RECOGNITIONThe viral RNA", "RNA", 146, 170], ["viral proteins", "PROTEIN", 172, 186], ["human immunoglobulin", "PROTEIN", 191, 211], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["biosensor technologies", "TEST", 18, 40], ["RECOGNITIONThe viral RNA", "TEST", 146, 170], ["viral proteins", "TEST", 172, 186], ["human immunoglobulin", "TREATMENT", 191, 211], ["viral RNA", "OBSERVATION", 161, 170]]], ["Target regions for viral RNA detection can be selected from any region of the RNA genome.", [["viral RNA", "RNA", 19, 28], ["RNA genome", "DNA", 78, 88], ["viral RNA detection", "TEST", 19, 38], ["viral RNA", "OBSERVATION", 19, 28], ["RNA genome", "OBSERVATION", 78, 88]]], ["Additionally, the nucleocapsid (N), 10-12 spike (S), 4,13-16 envelope (E) 17 and membrane (M) 18 proteins and viral proteases could also be the targets of detection.", [["membrane", "ANATOMY", 81, 89], ["nucleocapsid", "CELLULAR_COMPONENT", 18, 30], ["E) 17", "GENE_OR_GENE_PRODUCT", 71, 76], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["nucleocapsid (N), 10-12 spike (S), 4,13-16 envelope (E) 17", "PROTEIN", 18, 76], ["membrane (M) 18 proteins", "PROTEIN", 81, 105], ["viral proteases", "PROTEIN", 110, 125], ["the nucleocapsid (N)", "TEST", 14, 34], ["membrane (M) 18 proteins", "TEST", 81, 105], ["viral proteases", "PROBLEM", 110, 125], ["viral proteases", "OBSERVATION", 110, 125]]], ["In patients infected by SARS-CoV-1 in 2003, the immunoglobulin IgA was observed in the serum, followed by IgM and IgG.", [["serum", "ANATOMY", 87, 92], ["SARS", "DISEASE", 24, 28], ["patients", "ORGANISM", 3, 11], ["SARS-CoV-1", "ORGANISM", 24, 34], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 48, 62], ["IgA", "GENE_OR_GENE_PRODUCT", 63, 66], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["IgM", "GENE_OR_GENE_PRODUCT", 106, 109], ["IgG", "GENE_OR_GENE_PRODUCT", 114, 117], ["immunoglobulin IgA", "PROTEIN", 48, 66], ["IgM", "PROTEIN", 106, 109], ["IgG", "PROTEIN", 114, 117], ["patients", "SPECIES", 3, 11], ["SARS-CoV-1", "SPECIES", 24, 34], ["CoV", "TEST", 29, 32], ["the immunoglobulin IgA", "TEST", 44, 66], ["the serum", "TEST", 83, 92], ["IgM", "TEST", 106, 109], ["IgG", "TEST", 114, 117], ["infected", "OBSERVATION_MODIFIER", 12, 20]]], ["19 The IgM and IgG are useful for indicating whether the person has been infected, and whether the infection has triggered host immunological response.TARGETS OF RECOGNITIONNasopharyngeal swab and throat swab are the major sample collection methods for clinical diagnosis.", [["throat swab", "ANATOMY", 197, 208], ["sample", "ANATOMY", 223, 229], ["infection", "DISEASE", 99, 108], ["IgM", "GENE_OR_GENE_PRODUCT", 7, 10], ["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["person", "ORGANISM", 57, 63], ["IgM", "PROTEIN", 7, 10], ["IgG", "PROTEIN", 15, 18], ["person", "SPECIES", 57, 63], ["The IgM", "TEST", 3, 10], ["the infection", "PROBLEM", 95, 108], ["RECOGNITIONNasopharyngeal swab", "TEST", 162, 192], ["throat swab", "TEST", 197, 208], ["infected", "OBSERVATION", 73, 81], ["infection", "OBSERVATION", 99, 108], ["throat", "ANATOMY", 197, 203]]], ["Other samples may come from expectorated sputum, 20 saliva, serum, 11 and feces.", [["samples", "ANATOMY", 6, 13], ["sputum", "ANATOMY", 41, 47], ["saliva", "ANATOMY", 52, 58], ["serum", "ANATOMY", 60, 65], ["feces", "ANATOMY", 74, 79], ["sputum", "ORGANISM_SUBSTANCE", 41, 47], ["saliva", "ORGANISM_SUBSTANCE", 52, 58], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["feces", "ORGANISM_SUBSTANCE", 74, 79], ["Other samples", "TEST", 0, 13], ["expectorated sputum", "TEST", 28, 47], ["serum", "TEST", 60, 65]]], ["21 The speed and geographical range of the virus spread was unexpected.", [["the virus spread", "PROBLEM", 39, 55], ["virus spread", "OBSERVATION", 43, 55]]], ["It remained unclear whether the virus can be transmitted via aerosol and ambient air.", [["the virus", "PROBLEM", 28, 37], ["virus", "OBSERVATION", 32, 37]]], ["6 Thus, environmental detector of SARS-CoV-2 in the ambient air may help to clarify the transmission route.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 39, 44], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["the ambient air", "TREATMENT", 48, 63]]], ["Also, the circulated air in the ventilators in the intensive care unit may be a source of viral detection.RECOGNITION METHODSGenerally, the SARS-CoV-2 genomic RNA is one major target of recognition.", [["SARS", "DISEASE", 140, 144], ["SARS-CoV-2 genomic RNA", "RNA", 140, 162], ["SARS-CoV", "SPECIES", 140, 148], ["viral detection", "PROBLEM", 90, 105], ["the SARS", "TEST", 136, 144], ["circulated", "OBSERVATION_MODIFIER", 10, 20], ["air", "OBSERVATION", 21, 24], ["ventilators", "ANATOMY", 32, 43], ["viral", "OBSERVATION", 90, 95]]], ["The detection processes often involve the amplification of nucleic acid, such as the real-time reverse transcription polymerase chain reaction (RT-PCR).", [["nucleic acid", "CHEMICAL", 59, 71], ["nucleic acid", "SIMPLE_CHEMICAL", 59, 71], ["nucleic acid", "TEST", 59, 71], ["reverse transcription polymerase chain reaction", "PROBLEM", 95, 142], ["RT-PCR", "TEST", 144, 150]]], ["22 The drawback is on the time required, as this method requires a thermodynamic cycle which takes time.", [["a thermodynamic cycle", "TREATMENT", 65, 86]]], ["Apart from PCR-based methods, methods involving the nucleotide probes such as the nanoString technology can be used for SARS-Cov-2 detection (Canopy Bioscience, St. Louis, MO, USA).", [["nucleotide", "CHEMICAL", 52, 62], ["nucleotide", "CHEMICAL", 52, 62], ["PCR", "TEST", 11, 14], ["the nucleotide probes", "TREATMENT", 48, 69], ["the nanoString technology", "TREATMENT", 78, 103], ["SARS", "PROBLEM", 120, 124]]], ["This technology requires the synthesis of the nucleotide probe which has the antisense binding with the target.", [["nucleotide", "CHEMICAL", 46, 56], ["nucleotide", "CHEMICAL", 46, 56], ["the synthesis of the nucleotide probe", "TREATMENT", 25, 62]]], ["Fluorescent agents were linked to the probes so as to provide a means of detection.", [["Fluorescent agents", "TREATMENT", 0, 18]]], ["Probes can also be linked to gold nanoparticles.", [["Probes", "ORGANISM_SUBSTANCE", 0, 6], ["gold nanoparticles", "SIMPLE_CHEMICAL", 29, 47]]], ["[23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The concept was first proposed by F\u00f6rster in 1948.", [["[23] [24] [25] [26] [27] [28]", "CHEMICAL", 0, 29], ["[23] [24] [25] [26] [27] [28] [29] [30] [31] [32]", "SIMPLE_CHEMICAL", 0, 49]]], ["Theoretically, FRET can achieve detection resolutions far beyond the limitation of optical resolution, namely, at the 1-10 nm range.", [["resolution", "OBSERVATION_MODIFIER", 91, 101]]], ["Optical instruments that can get the specific FRET signals in situ have become one of the most powerful tools for many biological research fields, even superior than biochemical methods.", [["Optical instruments", "TREATMENT", 0, 19]]], ["Generally, there are two kinds of systems can be applied for monitoring FRET, that is, either using the intensity-based or utilizing the lifetime-based (the fluorescence-lifetime imaging microscopy) FRET imaging.", [["monitoring FRET", "TEST", 61, 76], ["the fluorescence", "TEST", 153, 169], ["lifetime imaging microscopy", "TEST", 170, 197], ["FRET imaging", "TEST", 199, 211]]], ["Through getting the signal of FRET events inside living cells/ tissues, the protein-protein interactions can be revealed, proteolytic cleavage may be further studied, and even the protein conformational changes can be analyzed.", [["cells", "ANATOMY", 56, 61], ["tissues", "ANATOMY", 63, 70], ["cells", "CELL", 56, 61], ["tissues", "TISSUE", 63, 70], ["FRET events", "PROBLEM", 30, 41], ["the protein-protein interactions", "TEST", 72, 104], ["proteolytic cleavage", "PROBLEM", 122, 142], ["the protein conformational changes", "PROBLEM", 176, 210], ["tissues", "ANATOMY", 63, 70]]], ["In addition, scientists found that this FRET strategy can be used to produce biological probes, that is, the biosensors in combination with the abovementioned optical platforms.RECOGNITION METHODSIn terms of detecting viral proteins, the sensing of proteinprotein interactions (like antibody-antigen binding or receptorligand) can be considered.", [["proteinprotein", "GENE_OR_GENE_PRODUCT", 249, 263], ["antibody-antigen", "GENE_OR_GENE_PRODUCT", 283, 299], ["viral proteins", "PROTEIN", 218, 232], ["antibody-antigen binding or receptorligand", "PROTEIN", 283, 325], ["this FRET strategy", "TREATMENT", 35, 53], ["the biosensors", "TREATMENT", 105, 119], ["viral proteins", "PROBLEM", 218, 232], ["proteinprotein interactions", "PROBLEM", 249, 276]]], ["Currently, antibodies represent the most effective recognition method.", [["antibodies", "PROTEIN", 11, 21]]], ["33 The antibody could be harvested from animal viral-challenge experiments with either N/S/E protein or from the blood samples of patients who are infected.", [["blood samples", "ANATOMY", 113, 126], ["blood samples", "ORGANISM_SUBSTANCE", 113, 126], ["patients", "ORGANISM", 130, 138], ["N/S/E protein", "PROTEIN", 87, 100], ["patients", "SPECIES", 130, 138], ["The antibody", "TEST", 3, 15], ["N/S/E protein", "TREATMENT", 87, 100], ["the blood samples", "TEST", 109, 126], ["infected", "PROBLEM", 147, 155], ["infected", "OBSERVATION", 147, 155]]], ["Apart from conventional antibodies, the antibody-mimic proteins represent novel approaches for target recognition.", [["antibodies", "PROTEIN", 24, 34], ["antibody-mimic proteins", "PROTEIN", 40, 63], ["conventional antibodies", "TEST", 11, 34], ["the antibody", "TEST", 36, 48], ["antibodies", "OBSERVATION", 24, 34]]], ["15, 34 This approach is to genetically modify certain regions of a protein, for example, fibronectin, 34 so that the modified protein can have noncovalent binding with the target macromolecule, thereby serving as the target recognition agent.", [["fibronectin", "GENE_OR_GENE_PRODUCT", 89, 100], ["fibronectin", "PROTEIN", 89, 100], ["modified protein", "PROTEIN", 117, 133], ["fibronectin", "TEST", 89, 100], ["noncovalent binding", "PROBLEM", 143, 162]]], ["Moreover, a promising design will be novel FRET-based biosensors.", [["novel FRET-based biosensors", "TREATMENT", 37, 64]]], ["Among these SARS-CoV-2 biosensors, the viral S protein-binding peptide (derived from the corresponding domain encoded by the human ACE2 gene) will be fused with the genes of FRET pair proteins (such as enhanced cyan fluorescent protein and enhanced yellow fluorescent protein).", [["human", "ORGANISM", 125, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 131, 135], ["cyan fluorescent protein", "GENE_OR_GENE_PRODUCT", 211, 235], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 249, 275], ["viral S protein", "PROTEIN", 39, 54], ["human ACE2 gene", "DNA", 125, 140], ["FRET pair proteins", "PROTEIN", 174, 192], ["enhanced cyan fluorescent protein", "PROTEIN", 202, 235], ["enhanced yellow fluorescent protein", "PROTEIN", 240, 275], ["human", "SPECIES", 125, 130], ["SARS-CoV", "SPECIES", 12, 20], ["human", "SPECIES", 125, 130], ["these SARS", "TEST", 6, 16], ["CoV", "TEST", 17, 20], ["the viral S protein", "TEST", 35, 54], ["binding peptide", "PROBLEM", 55, 70], ["the human ACE2 gene", "TREATMENT", 121, 140], ["FRET pair proteins", "PROBLEM", 174, 192], ["enhanced cyan fluorescent protein", "TEST", 202, 235]]], ["[23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In addition, the enzyme reaction (proteolytic cleavage by specific protease) may proceed during the infection of SARV-CoV-2 into human cells.", [["cells", "ANATOMY", 185, 190], ["infection", "DISEASE", 150, 159], ["[23] [24] [25] [26] [27] [28] [29] [30] [31] [32]", "CHEMICAL", 0, 49], ["[23] [24] [25] [26] [27] [28] [29] [30] [31] [32]", "SIMPLE_CHEMICAL", 0, 49], ["SARV-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["human", "ORGANISM", 179, 184], ["cells", "CELL", 185, 190], ["protease", "PROTEIN", 117, 125], ["SARV", "PROTEIN", 163, 167], ["human cells", "CELL_TYPE", 179, 190], ["human", "SPECIES", 179, 184], ["SARV-CoV", "SPECIES", 163, 171], ["human", "SPECIES", 179, 184], ["the enzyme reaction", "PROBLEM", 63, 82], ["proteolytic cleavage", "TREATMENT", 84, 104], ["specific protease", "TREATMENT", 108, 125], ["the infection", "PROBLEM", 146, 159], ["SARV", "TEST", 163, 167], ["CoV", "TEST", 168, 171]]], ["Similar to the FRET biosensor strategy, the specific peptide sequence can serve as a bait to be digested by the viral protease so that this kind of sensor can be an off-on signaling to present the existence of viral activity.", [["viral protease", "PROTEIN", 112, 126], ["the FRET biosensor strategy", "TREATMENT", 11, 38], ["the specific peptide sequence", "TEST", 40, 69], ["the viral protease", "TREATMENT", 108, 126], ["viral activity", "OBSERVATION", 210, 224]]], ["[35] [36] [37]SIGNAL AMPLIFICATION AND TRANSDUCTION DEVICESChromatographic presentation has been commonly used for simple, point-of-care assays.", [["SIGNAL AMPLIFICATION", "TEST", 14, 34]]], ["In the clinical laboratory, optic systems such as light detectors or charged-coupled devices were commonly used.", [["charged-coupled devices", "TREATMENT", 69, 92]]], ["Plasmonic photothermal biosensors using the nucleotide probe attached to a gold nanoparticle has been constructed to detect SARS-CoV-2.", [["nucleotide", "CHEMICAL", 44, 54], ["gold nanoparticle", "CHEMICAL", 75, 92], ["nucleotide", "CHEMICAL", 44, 54], ["gold nanoparticle", "SIMPLE_CHEMICAL", 75, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 124, 134], ["SARS-CoV", "SPECIES", 124, 132], ["Plasmonic photothermal biosensors", "TREATMENT", 0, 33], ["the nucleotide probe", "TREATMENT", 40, 60], ["a gold nanoparticle", "TREATMENT", 73, 92], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132]]], ["38 A localized surface plasmoncoupled fluorescence fiber-optic biosensor has been constructed for the detection of N protein of SARS-CoV-1.", [["surface", "ANATOMY", 15, 22], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 128, 138], ["N protein", "PROTEIN", 115, 124], ["SARS-CoV-1", "SPECIES", 128, 138], ["A localized surface plasmoncoupled fluorescence fiber", "TREATMENT", 3, 56], ["the detection", "TEST", 98, 111], ["SARS", "TEST", 128, 132], ["CoV", "TEST", 133, 136]]], ["11FUTURE PERSPECTIVESIn the past, significant technological achievements have been made in biosensors, including the recognition methods and the signal amplification and transduction devices.", [["the signal amplification and transduction devices", "TREATMENT", 141, 190], ["significant", "OBSERVATION_MODIFIER", 34, 45]]], ["These biosensor technologies can be used for the improvement of COVID-19 diagnosis assays in clinical laboratories, by offering higher sensitivity and specificity in a shorter amount of time, with a fewer number of manual steps and occupy a smaller space.", [["These biosensor technologies", "TREATMENT", 0, 28], ["COVID", "TEST", 64, 69], ["smaller", "OBSERVATION_MODIFIER", 241, 248]]], ["The biosensors can also be used to develop point-of-care devices, for example, connected to the intensive care ventilators.", [["care devices", "TREATMENT", 52, 64], ["the intensive care ventilators", "TREATMENT", 92, 122]]], ["Finally, environmental detectors of the virus or viral macromolecules in", [["the virus", "PROBLEM", 36, 45], ["viral macromolecules", "TREATMENT", 49, 69]]]], "PMC7436571": [["Robert (not the patient's true name) entered my clinic room and shook my hand without hesitation.", [["hand", "ANATOMY", 73, 77], ["patient", "ORGANISM", 16, 23], ["hand", "ORGANISM_SUBDIVISION", 73, 77], ["patient", "SPECIES", 16, 23]]], ["Aged in his late 60s, he had lived with type 1 diabetes for more than 50 years.", [["type 1 diabetes", "DISEASE", 40, 55], ["type 1 diabetes", "PROBLEM", 40, 55], ["diabetes", "OBSERVATION", 47, 55]]]], "PMC7415946": [], "d6e56458534f620318458a23e4b70b930d66a10c": [["INTRODUCTIONThe new SARS-CoV-2 coronavirus is the causative agent of the current pandemic of COVID-19.", [["SARS", "DISEASE", 20, 24], ["COVID-19", "CHEMICAL", 93, 101], ["SARS-CoV-2 coronavirus", "ORGANISM", 20, 42], ["CoV-2 coronavirus", "SPECIES", 25, 42], ["SARS-CoV-2 coronavirus", "SPECIES", 20, 42], ["COVID", "TEST", 93, 98]]], ["This highly pathogenic virus has quickly become the latest threat to modern life.", [["This highly pathogenic virus", "PROBLEM", 0, 28], ["pathogenic", "OBSERVATION_MODIFIER", 12, 22], ["virus", "OBSERVATION", 23, 28]]], ["From the end of 2019 and up to the redaction of this paper, this virus has infected over 17 million people, leading to mild symptoms of fever and to lung function reduction, severe acute respiratory syndrome (SARS), and even death.", [["lung", "ANATOMY", 149, 153], ["fever", "DISEASE", 136, 141], ["lung function reduction", "DISEASE", 149, 172], ["acute respiratory syndrome", "DISEASE", 181, 207], ["SARS", "DISEASE", 209, 213], ["death", "DISEASE", 225, 230], ["people", "ORGANISM", 100, 106], ["lung", "ORGAN", 149, 153], ["people", "SPECIES", 100, 106], ["this virus", "PROBLEM", 60, 70], ["mild symptoms", "PROBLEM", 119, 132], ["fever", "PROBLEM", 136, 141], ["lung function reduction", "TREATMENT", 149, 172], ["severe acute respiratory syndrome", "PROBLEM", 174, 207], ["even death", "PROBLEM", 220, 230], ["mild", "OBSERVATION_MODIFIER", 119, 123], ["fever", "OBSERVATION", 136, 141], ["lung", "ANATOMY", 149, 153], ["reduction", "OBSERVATION_MODIFIER", 163, 172], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["respiratory syndrome", "OBSERVATION", 187, 207]]], ["The current global death toll stands at 670,000; however, we are still far away from determining the final mortality figure.", [["death", "DISEASE", 19, 24], ["global", "OBSERVATION_MODIFIER", 12, 18], ["death", "OBSERVATION", 19, 24]]], ["In the absence of vaccines or effective antiviral treatments against SARS-CoV-2, it is important to understand how this virus appropriates the host translation apparatus and subverts the immune defenses of infected cells.", [["cells", "ANATOMY", 215, 220], ["SARS", "DISEASE", 69, 73], ["SARS-CoV-2", "ORGANISM", 69, 79], ["cells", "CELL", 215, 220], ["infected cells", "CELL_TYPE", 206, 220], ["SARS-CoV", "SPECIES", 69, 77], ["vaccines", "TREATMENT", 18, 26], ["effective antiviral treatments", "TREATMENT", 30, 60], ["SARS", "PROBLEM", 69, 73], ["this virus", "PROBLEM", 115, 125], ["infected cells", "PROBLEM", 206, 220], ["infected cells", "OBSERVATION", 206, 220]]], ["This can be the first step in the development of novel therapeutics.INTRODUCTIONAs intracellular parasites, virus replication depends on the translational machinery of their cellular hosts to translate viral transcripts.", [["intracellular", "ANATOMY", 83, 96], ["cellular", "ANATOMY", 174, 182], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["cellular", "CELL", 174, 182], ["viral transcripts", "RNA", 202, 219], ["novel therapeutics", "TREATMENT", 49, 67], ["intracellular parasites", "PROBLEM", 83, 106], ["virus replication", "TREATMENT", 108, 125], ["viral transcripts", "TREATMENT", 202, 219], ["parasites", "OBSERVATION", 97, 106]]], ["Thus, virus replication requires ribosomes, tRNA, and translation factors from the cell host.", [["cell", "ANATOMY", 83, 87], ["ribosomes", "CELLULAR_COMPONENT", 33, 42], ["tRNA", "CELLULAR_COMPONENT", 44, 48], ["cell", "CELL", 83, 87], ["ribosomes", "PROTEIN", 33, 42], ["translation factors", "PROTEIN", 54, 73], ["virus replication", "TREATMENT", 6, 23], ["tRNA", "TREATMENT", 44, 48], ["virus replication", "OBSERVATION", 6, 23]]], ["It is known that more frequently used codons are used for coding highly abundant proteins (Pan et al., 1998; Dana and Tuller, 2014; Quax et al., 2015; Diambra, 2017) .", [["codons", "TREATMENT", 38, 44]]], ["Virus genomes also have preferences in the codon usage, but, in this case, the bias is constrained by the host translational machinery (Shackelton et al., 2006) .", [["Virus", "ORGANISM", 0, 5], ["Virus genomes", "PROBLEM", 0, 13]]], ["In fact, the virus replication demands not only ribosomes but also a lot tRNA resources for the codons highest in demand (Chen et al., 2020) .", [["ribosomes", "CELLULAR_COMPONENT", 48, 57], ["a lot tRNA resources", "TREATMENT", 67, 87]]], ["The consumption of specific tRNAs for the virus replication could thus be an alternative to controlling host protein synthesis machinery as well as generating deleterious collateral effects on the function of the host cells.", [["collateral", "ANATOMY", 171, 181], ["cells", "ANATOMY", 218, 223], ["cells", "CELL", 218, 223], ["host cells", "CELL_TYPE", 213, 223], ["specific tRNAs", "TREATMENT", 19, 33], ["the virus replication", "TREATMENT", 38, 59], ["host protein synthesis machinery", "TREATMENT", 104, 136], ["deleterious", "OBSERVATION_MODIFIER", 159, 170], ["collateral", "OBSERVATION", 171, 181], ["host cells", "OBSERVATION", 213, 223]]], ["Recent evidence supports the idea that high codon usage similarity between virus and host can lead to a deleterious effect on the host (Chen et al., 2020) .", [["high codon usage similarity between virus", "PROBLEM", 39, 80], ["a deleterious effect", "PROBLEM", 102, 122], ["high codon", "OBSERVATION", 39, 49]]], ["Furthermore, Chen et al. (2020) have shown that codon composition of highly expressed viral genes regulates the tRNA availability, affecting the decoding time of codons in the infected cells.", [["cells", "ANATOMY", 185, 190], ["cells", "CELL", 185, 190], ["viral genes", "DNA", 86, 97], ["infected cells", "CELL_TYPE", 176, 190], ["codons in the infected cells", "PROBLEM", 162, 190], ["viral genes", "OBSERVATION", 86, 97], ["infected cells", "OBSERVATION", 176, 190]]], ["In this manner the viral infection can convert abundant codons into scarce codons, reshaping the human codon optimality pattern.", [["viral infection", "DISEASE", 19, 34], ["human", "ORGANISM", 97, 102], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["the viral infection", "PROBLEM", 15, 34], ["abundant codons into scarce codons", "PROBLEM", 47, 81], ["reshaping the human codon optimality pattern", "PROBLEM", 83, 127], ["viral", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 25, 34], ["scarce codons", "OBSERVATION", 68, 81], ["human codon optimality", "OBSERVATION", 97, 119]]], ["In this sense, it has been proposed that dysregulation of the tRNA pool can lead to disease (Dhindsa et al., 2020) .", [["dysregulation of the tRNA pool", "PROBLEM", 41, 71], ["disease", "PROBLEM", 84, 91]]], ["In fact, there is growing evidence supporting that synonymous variations in a coding sequence can affect its folding and/or resulting expression level (Tsai et al., 2008; Hunt et al., 2014; Buhr et al., 2016; Kirchner et al., 2017; von Herrmann et al., 2018; Dhindsa et al., 2020; Kim et al., 2020) .INTRODUCTIONIt is known that coronavirus genomes are poor in GC content (\u223c 40%) and that there exist a preferential use of A-ended or Uended codons in these genomes (Gu et al., 2004; Kandeel et al., 2020) .", [["coronavirus", "ORGANISM", 329, 340], ["coronavirus genomes", "DNA", 329, 348], ["synonymous variations", "PROBLEM", 51, 72], ["a coding sequence", "PROBLEM", 76, 93], ["coronavirus genomes", "PROBLEM", 329, 348], ["synonymous variations", "OBSERVATION", 51, 72], ["coronavirus genomes", "OBSERVATION", 329, 348]]], ["The last bias is usually characterized in the literature as the GC3 content.", [["GC3", "DNA", 64, 67], ["bias", "OBSERVATION", 9, 13]]], ["Indeed, the analysis performed by Gu et al. (2004) suggests that this compositional constraint is a major determinant to synonymous codon usage.", [["the analysis", "TEST", 8, 20], ["this compositional constraint", "PROBLEM", 65, 94], ["synonymous codon", "OBSERVATION", 121, 137]]], ["Here, we study recent proteomic data from SARS-CoV-2 infected cells (Bojkova et al., 2020) from a novel point of view.", [["cells", "ANATOMY", 62, 67], ["SARS-CoV-2", "CELL", 42, 52], ["cells", "CELL", 62, 67], ["SARS-CoV-2 infected cells", "CELL_LINE", 42, 67], ["SARS-CoV", "SPECIES", 42, 50], ["proteomic data", "TEST", 22, 36], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50]]], ["By considering the codon usage of the virus ORFeome, we characterize a set of genes whose expression could be affected by the massive demand of the tRNA which implies the virus replication.", [["tRNA", "CELLULAR_COMPONENT", 148, 152], ["virus ORFeome", "DNA", 38, 51], ["the tRNA", "TREATMENT", 144, 152], ["the virus replication", "TREATMENT", 167, 188], ["massive", "OBSERVATION_MODIFIER", 126, 133], ["virus replication", "OBSERVATION", 171, 188]]], ["We find that those host genes encoding proteins with similar codons to the virus ORFeome have a lower translational rate.", [["ORFeome", "GENE_OR_GENE_PRODUCT", 81, 88], ["virus ORFeome", "DNA", 75, 88], ["similar codons", "PROBLEM", 53, 67]]], ["Extrapolating this finding to highly expressed genes in lung, we find a small set of genes that can be downregulated.", [["lung", "ANATOMY", 56, 60], ["lung", "ORGAN", 56, 60], ["lung", "ANATOMY", 56, 60], ["small", "OBSERVATION_MODIFIER", 72, 77]]], ["These genes are involved in translation, immune systems, and cell calcification, to name a few, and their roles in the SARS-CoV-2 cell pathogenesis should be the target of further studies.MATERIALS AND METHODSThe coding sequences associated with the genome of SARS-CoV and SARS-CoV-2 were obtained from the NCBI (NC_004718.3 and NC_045512.2, respectively).", [["immune systems", "ANATOMY", 41, 55], ["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 130, 134], ["calcification", "DISEASE", 66, 79], ["SARS", "DISEASE", 119, 123], ["SARS", "DISEASE", 260, 264], ["cell", "CELL", 61, 65], ["2 cell", "CELL", 128, 134], ["SARS-CoV", "ORGANISM", 260, 268], ["SARS-CoV-2", "ORGANISM", 273, 283], ["SARS-CoV and SARS-CoV-2", "DNA", 260, 283], ["SARS-CoV", "SPECIES", 260, 268], ["SARS-CoV", "SPECIES", 273, 281], ["immune systems", "PROBLEM", 41, 55], ["cell calcification", "PROBLEM", 61, 79], ["the SARS", "PROBLEM", 115, 123], ["CoV-2 cell pathogenesis", "PROBLEM", 124, 147], ["further studies", "TEST", 172, 187], ["METHODSThe coding sequences", "TEST", 202, 229], ["SARS", "PROBLEM", 260, 264], ["CoV", "PROBLEM", 265, 268], ["SARS", "PROBLEM", 273, 277], ["CoV", "TEST", 278, 281], ["NC_", "TEST", 313, 316], ["NC", "TEST", 329, 331], ["cell calcification", "OBSERVATION", 61, 79]]], ["Highly expressed genes in the lung and arterial tissues were retrieved from the GTEx portal (gtexportal.org).", [["lung", "ANATOMY", 30, 34], ["arterial tissues", "ANATOMY", 39, 55], ["lung", "ORGAN", 30, 34], ["arterial tissues", "TISSUE", 39, 55], ["GTEx portal", "MULTI-TISSUE_STRUCTURE", 80, 91], ["genes", "OBSERVATION", 17, 22], ["lung", "ANATOMY", 30, 34], ["arterial tissues", "ANATOMY", 39, 55], ["GTEx", "ANATOMY_MODIFIER", 80, 84], ["portal", "ANATOMY", 85, 91]]], ["Proteomic and translatomic data from infected CACO-2 cells were retrieved from Supplementary Material of Bojkova et al. (2020) , which are publicly available (ProteomeXchange repository, ID = PXD017710).", [["CACO-2 cells", "ANATOMY", 46, 58], ["CACO-2 cells", "CELL", 46, 58], ["CACO-2 cells", "CELL_LINE", 46, 58], ["Proteomic", "TEST", 0, 9], ["translatomic data", "TEST", 14, 31], ["infected CACO-2 cells", "TREATMENT", 37, 58]]], ["These data contain protein levels from 6,381 proteins and translational rate from 2,715 proteins, and the proteomic information is consequently not available for many proteins.MATERIALS AND METHODSGiven the coding sequence s, we compute the codon usage frequency as f s (c) = N c L s , where L s is total number of codons in the sequence s, and N c is the number of times that codon c is present in s.", [["N c", "GENE_OR_GENE_PRODUCT", 345, 348], ["6,381 proteins", "PROTEIN", 39, 53], ["2,715 proteins", "PROTEIN", 82, 96], ["coding sequence", "DNA", 207, 222], ["N c", "PROTEIN", 345, 348], ["codon c", "PROTEIN", 377, 384], ["These data", "TEST", 0, 10], ["protein levels", "TEST", 19, 33], ["translational rate", "TEST", 58, 76], ["many proteins", "PROBLEM", 162, 175], ["N c L s", "PROBLEM", 276, 283]]], ["In a similar manner, we define codon usage frequency relative to the viral ORFome:RESULTSWe study the codon composition of two complete coronavirus genomes by measuring the percentage of G and C nucleotides at the wobble position of the codons (GC3 content).", [["nucleotides", "CHEMICAL", 195, 206], ["viral ORFome", "DNA", 69, 81], ["coronavirus genomes", "DNA", 136, 155], ["GC3", "DNA", 245, 248], ["codon usage frequency", "PROBLEM", 31, 52], ["RESULTSWe study", "TEST", 82, 97], ["two complete coronavirus genomes", "PROBLEM", 123, 155], ["G and C nucleotides", "TREATMENT", 187, 206], ["coronavirus genomes", "OBSERVATION", 136, 155], ["wobble position", "OBSERVATION", 214, 229]]], ["Figure 1A depicts the GC3 content of each annotated coding sequence of the SARS-CoV and SARS-CoV-2.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV", "ORGANISM", 75, 83], ["SARS-CoV-2", "ORGANISM", 88, 98], ["GC3", "DNA", 22, 25], ["SARS-CoV-2", "DNA", 88, 98], ["SARS-CoV", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 88, 96], ["the SARS", "TEST", 71, 79], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96]]], ["This analysis reveals that, in agreement with Gu et al. (2004) and Kandeel et al. (2020) , codons preferentially used by these viruses are associated with a lower GC3 content than that expected from the random use of nucleotides.", [["nucleotides", "CHEMICAL", 217, 228], ["GC3", "DNA", 163, 166], ["This analysis", "TEST", 0, 13], ["codons", "TREATMENT", 91, 97], ["a lower GC3 content", "PROBLEM", 155, 174], ["nucleotides", "TREATMENT", 217, 228], ["viruses", "OBSERVATION", 127, 134]]], ["In particular, the ORFs corresponding to the proteins ORF1ab, ORF1a, surface, ORF6, ORF7a, and ORF8 exhibit a very low content of GC3.", [["surface", "ANATOMY", 69, 76], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 54, 60], ["ORF1a", "GENE_OR_GENE_PRODUCT", 62, 67], ["surface", "CELLULAR_COMPONENT", 69, 76], ["ORF6", "GENE_OR_GENE_PRODUCT", 78, 82], ["ORF7a", "GENE_OR_GENE_PRODUCT", 84, 89], ["ORF8", "GENE_OR_GENE_PRODUCT", 95, 99], ["ORFs", "DNA", 19, 23], ["ORF1ab", "PROTEIN", 54, 60], ["ORF1a", "PROTEIN", 62, 67], ["ORF6", "PROTEIN", 78, 82], ["ORF7a", "PROTEIN", 84, 89], ["ORF8", "PROTEIN", 95, 99], ["GC3", "DNA", 130, 133], ["the ORFs", "PROBLEM", 15, 23], ["the proteins ORF1ab", "TEST", 41, 60], ["ORF1a", "TEST", 62, 67], ["surface", "TEST", 69, 76], ["ORF6", "TEST", 78, 82], ["ORF7a", "TEST", 84, 89], ["ORF8", "TEST", 95, 99], ["a very low content of GC3", "PROBLEM", 108, 133]]], ["Specifically, the last two proteins are highly expressed at 10 h post-infection (PI), as can be seen in Figure 1B .RESULTSAs was highlighted previously, this high expression of viral proteins could lead to an imbalance in the tRNA pool needed for the normal synthesis of the proteins of the host cell.", [["cell", "ANATOMY", 296, 300], ["infection", "DISEASE", 70, 79], ["host cell", "CELL", 291, 300], ["viral proteins", "PROTEIN", 177, 191], ["host cell", "CELL_TYPE", 291, 300], ["infection", "PROBLEM", 70, 79], ["viral proteins", "PROBLEM", 177, 191], ["an imbalance in the tRNA pool", "PROBLEM", 206, 235], ["infection", "OBSERVATION", 70, 79], ["viral proteins", "OBSERVATION", 177, 191], ["host cell", "OBSERVATION", 291, 300]]], ["Of course, as tRNA pools depend on the cell types, the postulated imbalance could be a tissue-dependent feature.", [["cell", "ANATOMY", 39, 43], ["tissue", "ANATOMY", 87, 93], ["cell", "CELL", 39, 43], ["tissue", "TISSUE", 87, 93], ["tRNA pools", "PROBLEM", 14, 24], ["a tissue-dependent feature", "PROBLEM", 85, 111], ["cell types", "OBSERVATION", 39, 49], ["imbalance", "OBSERVATION", 66, 75], ["dependent", "OBSERVATION_MODIFIER", 94, 103]]], ["To check this hypothesis, we make use of the recently available data about the proteome profile and translational rate in SARS-CoV-2-infected cells (Bojkova et al., 2020) .", [["cells", "ANATOMY", 142, 147], ["SARS-CoV-2", "ORGANISM", 122, 132], ["cells", "CELL", 142, 147], ["SARS-CoV-2-infected cells", "CELL_LINE", 122, 147], ["SARS-CoV", "SPECIES", 122, 130], ["the proteome profile", "TEST", 75, 95], ["translational rate", "TEST", 100, 118], ["SARS", "TEST", 122, 126], ["CoV", "TEST", 127, 130], ["infected cells", "PROBLEM", 133, 147]]], ["In this study, a CACO-2 cell line was infected with SARS-CoV-2 and mocked, and the last one was used as the control.", [["CACO-2 cell line", "ANATOMY", 17, 33], ["CACO-2 cell line", "CELL", 17, 33], ["CACO-2 cell line", "CELL_LINE", 17, 33], ["SARS-CoV", "SPECIES", 52, 60], ["this study", "TEST", 3, 13], ["a CACO-2 cell line", "TREATMENT", 15, 33], ["cell line", "OBSERVATION", 24, 33]]], ["From this proteome, we selected the coding sequences corresponding to the 100 most abundant proteins in the mock infected cells at 10 h PI.", [["cells", "ANATOMY", 122, 127], ["cells", "CELL", 122, 127], ["mock infected cells", "CELL_TYPE", 108, 127], ["the coding sequences", "TEST", 32, 52], ["infected cells", "OBSERVATION", 113, 127]]], ["We then computed the codon correlation (CCorr) between the codon usage of each one of these sequences and the codon usage of all coding sequences in SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 149, 159], ["SARS-CoV-2", "DNA", 149, 159], ["SARS-CoV", "SPECIES", 149, 157], ["these sequences", "TEST", 86, 101], ["CoV", "TEST", 154, 157]]], ["Figure 2 depicts a scatter plot of the translational rate of these genes from SARS-CoV-2-infected cells vs. the corresponding CCorr (red dots).", [["cells", "ANATOMY", 98, 103], ["SARS", "DISEASE", 78, 82], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["cells", "CELL", 98, 103], ["CCorr", "GENE_OR_GENE_PRODUCT", 126, 131], ["infected cells", "CELL_TYPE", 89, 103], ["CCorr", "PROTEIN", 126, 131], ["a scatter plot", "TEST", 17, 31], ["SARS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["infected cells", "PROBLEM", 89, 103], ["infected cells", "OBSERVATION", 89, 103]]], ["The black line is the adjusted linear model, which shows a significant and negative correlation between the translation rate and the codon composition of each sequence.", [["the translation rate", "TEST", 104, 124], ["black line", "OBSERVATION", 4, 14], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["negative", "OBSERVATION", 75, 83]]], ["This means that the translational rate of coding sequence in SARS-CoV-2-infected cells is lower than in mockinfected cells.", [["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 117, 122], ["SARS", "DISEASE", 61, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["cells", "CELL", 81, 86], ["cells", "CELL", 117, 122], ["coding sequence", "DNA", 42, 57], ["SARS-CoV-2-infected cells", "CELL_LINE", 61, 86], ["mockinfected cells", "CELL_TYPE", 104, 122], ["SARS-CoV", "SPECIES", 61, 69], ["coding sequence", "TEST", 42, 57], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["infected cells", "PROBLEM", 72, 86], ["infected cells", "OBSERVATION", 72, 86], ["mockinfected cells", "OBSERVATION", 104, 122]]], ["Although the correlation (\u03c1 = \u22120.26) with codon composition is not high, reflecting the fact that other factors could be regulating the translation rate, it is significant at a value of 0.05 (p-value = 0.024 < 0.05).RESULTSThis analysis suggests then that the codon composition of highly expressed host-genes is a determinant of its own translation rate and that viral replication induces a particular case of epistasis, which could affect host cell proteostasis.", [["cell", "ANATOMY", 445, 449], ["host cell", "CELL", 440, 449], ["highly expressed host-genes", "DNA", 281, 308], ["the correlation", "TEST", 9, 24], ["codon composition", "TEST", 42, 59], ["the translation rate", "TEST", 132, 152], ["p-value", "TEST", 192, 199], ["RESULTSThis analysis", "TEST", 216, 236], ["viral replication", "PROBLEM", 363, 380], ["epistasis", "PROBLEM", 410, 419], ["significant", "OBSERVATION_MODIFIER", 160, 171], ["viral replication", "OBSERVATION", 363, 380], ["epistasis", "OBSERVATION", 410, 419], ["host cell proteostasis", "OBSERVATION", 440, 462]]], ["Consequently, we find it relevant to extrapolate this phenomenon to cells affected by SARS-CoV-2.", [["cells", "ANATOMY", 68, 73], ["SARS", "DISEASE", 86, 90], ["cells", "CELL", 68, 73], ["SARS-CoV-2", "ORGANISM", 86, 96], ["SARS-CoV", "SPECIES", 86, 94], ["CoV", "TEST", 91, 94]]], ["In this sense, the ACE2 receptor has been identified as the SARS-CoV-2 cell entry.", [["cell", "ANATOMY", 71, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["cell", "CELL", 71, 75], ["ACE2 receptor", "PROTEIN", 19, 32], ["the ACE2 receptor", "TEST", 15, 32], ["the SARS", "TEST", 56, 64]]], ["Even though ACE2 transcript is present in almost all organs, the surface expression of ACE2 protein is present in lung alveolar epithelial cells and arterial and venous endothelial cells (Hamming et al., 2004) .", [["organs", "ANATOMY", 53, 59], ["surface", "ANATOMY", 65, 72], ["lung alveolar epithelial cells", "ANATOMY", 114, 144], ["arterial", "ANATOMY", 149, 157], ["venous endothelial cells", "ANATOMY", 162, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["organs", "ORGAN", 53, 59], ["surface", "CELLULAR_COMPONENT", 65, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["lung alveolar epithelial cells", "CELL", 114, 144], ["arterial", "CELL", 149, 157], ["venous endothelial cells", "CELL", 162, 186], ["ACE2", "PROTEIN", 12, 16], ["ACE2 protein", "PROTEIN", 87, 99], ["lung alveolar epithelial cells", "CELL_TYPE", 114, 144], ["arterial and venous endothelial cells", "CELL_TYPE", 149, 186], ["ACE2 transcript", "TREATMENT", 12, 27], ["ACE2 protein", "TEST", 87, 99], ["transcript", "OBSERVATION", 17, 27], ["ACE2 protein", "OBSERVATION", 87, 99], ["lung", "ANATOMY", 114, 118], ["alveolar", "ANATOMY_MODIFIER", 119, 127], ["epithelial cells", "OBSERVATION", 128, 144], ["arterial", "ANATOMY_MODIFIER", 149, 157], ["venous endothelial", "ANATOMY", 162, 180]]], ["For that reason, we elected to analyze the most expressed genes in lung and arterial tissues extracted from the GTEx database, two main targets of the SARS-CoV-2 infection.", [["lung", "ANATOMY", 67, 71], ["arterial tissues", "ANATOMY", 76, 92], ["SARS", "DISEASE", 151, 155], ["infection", "DISEASE", 162, 171], ["lung", "ORGAN", 67, 71], ["arterial tissues", "TISSUE", 76, 92], ["SARS-CoV-2", "ORGANISM", 151, 161], ["SARS-CoV-2", "SPECIES", 151, 161], ["the SARS", "PROBLEM", 147, 155], ["CoV-2 infection", "PROBLEM", 156, 171], ["lung", "ANATOMY", 67, 71], ["arterial tissues", "ANATOMY", 76, 92], ["main", "OBSERVATION_MODIFIER", 131, 135], ["targets", "OBSERVATION_MODIFIER", 136, 143], ["SARS", "OBSERVATION", 151, 155], ["infection", "OBSERVATION", 162, 171]]], ["To this end, we select the 100 most expressed genes in these tissues and compute the CCorr for each sequence.", [["tissues", "ANATOMY", 61, 68], ["tissues", "TISSUE", 61, 68], ["CCorr", "GENE_OR_GENE_PRODUCT", 85, 90], ["CCorr", "DNA", 85, 90]]], ["Figure 3A shows that the codon composition profile of the most expressed genes from both lung and CACO-2 cells types are different, it is evident that the lung cells share fewer codons in common with the SARS-CoV-2 than the CACO-2 cells.", [["lung", "ANATOMY", 89, 93], ["CACO-2 cells", "ANATOMY", 98, 110], ["lung cells", "ANATOMY", 155, 165], ["CACO-2 cells", "ANATOMY", 224, 236], ["SARS", "DISEASE", 204, 208], ["lung", "ORGAN", 89, 93], ["CACO-2 cells", "CELL", 98, 110], ["lung cells", "CELL", 155, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 204, 214], ["CACO-2 cells", "CELL", 224, 236], ["lung cells", "CELL_TYPE", 155, 165], ["CACO-2 cells", "CELL_LINE", 224, 236], ["the codon composition profile", "PROBLEM", 21, 50], ["the lung cells", "PROBLEM", 151, 165], ["the SARS", "TEST", 200, 208], ["CoV", "TEST", 209, 212], ["both", "ANATOMY_MODIFIER", 84, 88], ["lung", "ANATOMY", 89, 93], ["lung", "ANATOMY", 155, 159]]], ["On the other hand, the codon composition profile of the highly expressed genes in arterial tissue are quite similar to the genes associated with the lung (Figure 3B ).", [["arterial tissue", "ANATOMY", 82, 97], ["lung", "ANATOMY", 149, 153], ["arterial tissue", "TISSUE", 82, 97], ["lung", "ORGAN", 149, 153], ["arterial tissue", "ANATOMY", 82, 97], ["lung", "ANATOMY", 149, 153]]], ["Consequently, the tRNAs pool used for the virus could be scarcer both in lung and arterial cells than in the CACO-2 cells.RESULTSWe search for those genes, highly expressed in the lung tissue, which could be affected by the depletion of the tRNAs consumed by virus replication.", [["lung", "ANATOMY", 73, 77], ["arterial cells", "ANATOMY", 82, 96], ["CACO-2 cells", "ANATOMY", 109, 121], ["lung tissue", "ANATOMY", 180, 191], ["lung", "ORGAN", 73, 77], ["arterial cells", "CELL", 82, 96], ["CACO-2 cells", "CELL", 109, 121], ["lung tissue", "TISSUE", 180, 191], ["lung and arterial cells", "CELL_TYPE", 73, 96], ["CACO-2 cells", "CELL_LINE", 109, 121], ["the tRNAs pool", "TREATMENT", 14, 28], ["the virus", "PROBLEM", 38, 47], ["the tRNAs", "TREATMENT", 237, 246], ["virus replication", "TREATMENT", 259, 276], ["lung", "ANATOMY", 73, 77], ["arterial cells", "ANATOMY", 82, 96], ["CACO", "ANATOMY", 109, 113], ["2 cells", "ANATOMY_MODIFIER", 114, 121], ["lung tissue", "ANATOMY", 180, 191]]], ["They are those whose codon composition is similar to SARS-CoV-2 (CCorr > 0.25); these are listed in Table 1 .", [["SARS-CoV", "SPECIES", 53, 61], ["SARS", "TEST", 53, 57], ["CoV", "TEST", 58, 61], ["CCorr", "TEST", 65, 70]]], ["This test identified significant differences between these groups (p-value = 0.0007), as it can be seen in Figure 3D .", [["This test", "TEST", 0, 9], ["p-value", "TEST", 67, 74], ["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["We want to remark that, since there is still no available data on translational rate from lung cells, the last analysis was performed by using translational rate data available from CACO-2 cells, although we know that this data would be underestimating the difference between these two groups of genes.", [["lung cells", "ANATOMY", 90, 100], ["CACO-2 cells", "ANATOMY", 182, 194], ["lung cells", "CELL", 90, 100], ["CACO-2 cells", "CELL", 182, 194], ["lung cells", "CELL_TYPE", 90, 100], ["CACO-2 cells", "CELL_LINE", 182, 194], ["the last analysis", "TEST", 102, 119], ["translational rate data", "TEST", 143, 166], ["lung", "ANATOMY", 90, 94]]], ["Furthermore, we performed a GO term enrichment analysis over the 27 genes listed in Table 1 ; their translation rates are decreased by means of the Enrichr online software (Chen et al., 2013) .", [["27 genes", "DNA", 65, 73], ["a GO term enrichment analysis", "TREATMENT", 26, 55], ["decreased", "OBSERVATION_MODIFIER", 122, 131]]], ["Figure 4 illustrates the main enrichment pathways.", [["main", "OBSERVATION_MODIFIER", 25, 29], ["enrichment pathways", "OBSERVATION", 30, 49]]], ["This analysis reveals that codon usage could promote extensive changes in the translation machinery of the host in agreement with previous report in CACO-2 cells (Bojkova et al., 2020) .", [["CACO-2 cells", "ANATOMY", 149, 161], ["CACO-2 cells", "CELL", 149, 161], ["CACO-2 cells", "CELL_LINE", 149, 161], ["This analysis", "TEST", 0, 13], ["codon usage", "TREATMENT", 27, 38], ["extensive", "OBSERVATION_MODIFIER", 53, 62]]], ["It is known that when canonical translation is impaired, as part of the host defense program, specific 40S ribosomal subunits are needed to support uncapped viral mRNA translation (Kwan and Thompson, 2019) .RESULTSOur list of genes from lung is enriched with several ribosomal proteins that constitute both 40S (RPS6, RPS3A, RPS7, RPSA, RPS25, RPS13, RPS12, and RPS27A) and 60S (RPL4, RPL5, RPL21, RPLP1, RPL34, RPL9, RPL24, and RPL17) ribosomal subunits.", [["lung", "ANATOMY", 237, 241], ["ribosomal", "ANATOMY", 267, 276], ["lung", "ORGAN", 237, 241], ["ribosomal", "CELLULAR_COMPONENT", 267, 276], ["40S", "GENE_OR_GENE_PRODUCT", 307, 310], ["RPS6", "GENE_OR_GENE_PRODUCT", 312, 316], ["RPS3A", "GENE_OR_GENE_PRODUCT", 318, 323], ["RPS7", "GENE_OR_GENE_PRODUCT", 325, 329], ["RPSA", "GENE_OR_GENE_PRODUCT", 331, 335], ["RPS25", "GENE_OR_GENE_PRODUCT", 337, 342], ["RPS13", "GENE_OR_GENE_PRODUCT", 344, 349], ["RPS12", "GENE_OR_GENE_PRODUCT", 351, 356], ["RPS27A", "GENE_OR_GENE_PRODUCT", 362, 368], ["60S", "GENE_OR_GENE_PRODUCT", 374, 377], ["RPL4", "GENE_OR_GENE_PRODUCT", 379, 383], ["RPL5", "GENE_OR_GENE_PRODUCT", 385, 389], ["RPL21", "GENE_OR_GENE_PRODUCT", 391, 396], ["RPLP1", "GENE_OR_GENE_PRODUCT", 398, 403], ["RPL34", "GENE_OR_GENE_PRODUCT", 405, 410], ["RPL9", "GENE_OR_GENE_PRODUCT", 412, 416], ["RPL24", "GENE_OR_GENE_PRODUCT", 418, 423], ["RPL17", "GENE_OR_GENE_PRODUCT", 429, 434], ["40S ribosomal subunits", "PROTEIN", 103, 125], ["viral mRNA", "RNA", 157, 167], ["ribosomal proteins", "PROTEIN", 267, 285], ["40S", "PROTEIN", 307, 310], ["RPS6", "PROTEIN", 312, 316], ["RPS3A", "PROTEIN", 318, 323], ["RPS7", "PROTEIN", 325, 329], ["RPSA", "PROTEIN", 331, 335], ["RPS25", "PROTEIN", 337, 342], ["RPS13", "PROTEIN", 344, 349], ["RPS12", "PROTEIN", 351, 356], ["RPS27A", "PROTEIN", 362, 368], ["60S", "PROTEIN", 374, 377], ["RPL4", "PROTEIN", 379, 383], ["RPL5", "PROTEIN", 385, 389], ["RPL21", "PROTEIN", 391, 396], ["RPLP1", "PROTEIN", 398, 403], ["RPL34", "PROTEIN", 405, 410], ["RPL9", "PROTEIN", 412, 416], ["RPL24", "PROTEIN", 418, 423], ["RPL17", "PROTEIN", 429, 434], ["ribosomal subunits", "PROTEIN", 436, 454], ["specific 40S ribosomal subunits", "TREATMENT", 94, 125], ["several ribosomal proteins", "TEST", 259, 285], ["RPS6", "TEST", 312, 316], ["RPS3A", "TEST", 318, 323], ["RPS7", "TEST", 325, 329], ["RPSA", "TEST", 331, 335], ["RPS25", "TEST", 337, 342], ["RPS13", "TEST", 344, 349], ["RPS12", "TEST", 351, 356], ["RPS27A", "TEST", 362, 368], ["RPL4", "TEST", 379, 383], ["RPL5", "TEST", 385, 389], ["RPL21", "TEST", 391, 396], ["RPLP1", "TEST", 398, 403], ["RPL34", "TEST", 405, 410], ["RPL9", "TREATMENT", 412, 416], ["RPL24", "TREATMENT", 418, 423], ["ribosomal subunits", "TREATMENT", 436, 454], ["viral mRNA", "OBSERVATION", 157, 167], ["lung", "ANATOMY", 237, 241], ["ribosomal proteins", "OBSERVATION", 267, 285]]], ["Many of them also appear in the set of genes derived from arterial tissue.", [["arterial tissue", "ANATOMY", 58, 73], ["arterial tissue", "TISSUE", 58, 73], ["genes", "OBSERVATION", 39, 44], ["arterial tissue", "OBSERVATION", 58, 73]]], ["All of them belong to the nonsensemediated decay pathway that control the mRNAs with abnormal termination.", [["mRNAs", "RNA", 74, 79], ["abnormal termination", "PROBLEM", 85, 105], ["abnormal", "OBSERVATION_MODIFIER", 85, 93], ["termination", "OBSERVATION_MODIFIER", 94, 105]]], ["The termination codon can be recognized if the 3 \u2032 untranslated region is short or if it does not have an exon junction complex downstream of the termination codon (Nicholson et al., 2010) .", [["3 \u2032 untranslated region", "DNA", 47, 70], ["exon junction complex", "PROTEIN", 106, 127], ["termination codon", "DNA", 146, 163], ["The termination codon", "TREATMENT", 0, 21]]], ["These genes are also part of the process of SRP-dependent co-translational protein destined for the endoplasmic reticulum.RESULTSIt is known that these proteins are involved in translation particularly the gene EEF1A1, an isoform of the alpha subunit of the elongation factor-1 expressed in lungs and arteries, which is responsible for the GTP-dependent binding of aminoacyl-tRNA to the ribosome.", [["endoplasmic reticulum", "ANATOMY", 100, 121], ["lungs", "ANATOMY", 291, 296], ["arteries", "ANATOMY", 301, 309], ["ribosome", "ANATOMY", 387, 395], ["GTP", "CHEMICAL", 340, 343], ["aminoacyl-tRNA", "CHEMICAL", 365, 379], ["GTP", "CHEMICAL", 340, 343], ["aminoacyl", "CHEMICAL", 365, 374], ["SRP", "GENE_OR_GENE_PRODUCT", 44, 47], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 100, 121], ["EEF1A1", "GENE_OR_GENE_PRODUCT", 211, 217], ["alpha subunit of the elongation factor-1", "GENE_OR_GENE_PRODUCT", 237, 277], ["lungs", "ORGAN", 291, 296], ["arteries", "MULTI-TISSUE_STRUCTURE", 301, 309], ["GTP", "SIMPLE_CHEMICAL", 340, 343], ["ribosome", "CELLULAR_COMPONENT", 387, 395], ["SRP-dependent co-translational protein", "PROTEIN", 44, 82], ["EEF1A1", "DNA", 211, 217], ["alpha subunit", "PROTEIN", 237, 250], ["elongation factor-1", "PROTEIN", 258, 277], ["SRP", "PROBLEM", 44, 47], ["dependent co-translational protein", "PROBLEM", 48, 82], ["the endoplasmic reticulum", "PROBLEM", 96, 121], ["the elongation factor", "PROBLEM", 254, 275], ["the GTP", "PROBLEM", 336, 343], ["aminoacyl-tRNA", "TREATMENT", 365, 379], ["dependent", "OBSERVATION_MODIFIER", 48, 57], ["co-translational protein destined", "OBSERVATION", 58, 91], ["endoplasmic reticulum", "OBSERVATION", 100, 121], ["elongation", "OBSERVATION_MODIFIER", 258, 268], ["lungs", "ANATOMY", 291, 296], ["arteries", "ANATOMY", 301, 309]]], ["Beyond its function in translation, EEF1A1 takes part in the innate immune system by activating directly the transcription of IFN-gamma (Maruyama et al., 2007) .", [["EEF1A1", "GENE_OR_GENE_PRODUCT", 36, 42], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 126, 135], ["EEF1A1", "PROTEIN", 36, 42], ["IFN-gamma", "PROTEIN", 126, 135]]], ["IFN-gamma activates immune cells, such as macrophages and natural killer cells, and stimulates the major histocompatibility complex (MHC) II-dependent presentation of antigens to the immune system (Schroder et al., 2004) .", [["immune cells", "ANATOMY", 20, 32], ["macrophages", "ANATOMY", 42, 53], ["natural killer cells", "ANATOMY", 58, 78], ["immune system", "ANATOMY", 183, 196], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 0, 9], ["immune cells", "CELL", 20, 32], ["macrophages", "CELL", 42, 53], ["natural killer cells", "CELL", 58, 78], ["MHC) II", "GENE_OR_GENE_PRODUCT", 133, 140], ["IFN-gamma", "PROTEIN", 0, 9], ["immune cells", "CELL_TYPE", 20, 32], ["macrophages", "CELL_TYPE", 42, 53], ["natural killer cells", "CELL_TYPE", 58, 78], ["major histocompatibility complex (MHC) II", "PROTEIN", 99, 140], ["antigens", "PROTEIN", 167, 175], ["IFN", "TEST", 0, 3], ["immune cells", "PROBLEM", 20, 32], ["macrophages", "PROBLEM", 42, 53], ["natural killer cells", "TREATMENT", 58, 78], ["immune cells", "OBSERVATION", 20, 32], ["natural killer cells", "OBSERVATION", 58, 78]]], ["This process could be downregulated due to a decrease in the translation rate of EEF1A1.", [["EEF1A1", "GENE_OR_GENE_PRODUCT", 81, 87], ["EEF1A1", "PROTEIN", 81, 87], ["a decrease", "PROBLEM", 43, 53], ["decrease", "OBSERVATION_MODIFIER", 45, 53]]], ["Furthermore, B2M, another gene in the list of decreased translational rate, encodes one of the proteins that conform MHC class I found on the cell surface of all nucleated cells (Bernier, 1980) .", [["cell surface", "ANATOMY", 142, 154], ["nucleated cells", "ANATOMY", 162, 177], ["B2M", "GENE_OR_GENE_PRODUCT", 13, 16], ["MHC class I", "GENE_OR_GENE_PRODUCT", 117, 128], ["cell surface", "CELLULAR_COMPONENT", 142, 154], ["cells", "CELL", 172, 177], ["B2M", "DNA", 13, 16], ["MHC class I", "PROTEIN", 117, 128], ["nucleated cells", "CELL_TYPE", 162, 177], ["decreased translational rate", "PROBLEM", 46, 74], ["B2M", "OBSERVATION", 13, 16], ["nucleated cells", "OBSERVATION", 162, 177]]], ["Together with TXNIP, RPS3A, and RPS27A, it is involved in the antigen processing and presentation.", [["TXNIP", "GENE_OR_GENE_PRODUCT", 14, 19], ["RPS3A", "GENE_OR_GENE_PRODUCT", 21, 26], ["RPS27A", "GENE_OR_GENE_PRODUCT", 32, 38], ["TXNIP", "PROTEIN", 14, 19], ["RPS3A", "PROTEIN", 21, 26], ["RPS27A", "PROTEIN", 32, 38], ["TXNIP", "TEST", 14, 19], ["RPS3A", "TEST", 21, 26], ["TXNIP", "OBSERVATION", 14, 19]]], ["Moreover, this gene, along with S100A11, HSP90AB1, and also EEF1A1, regulates the exocytosis of granules containing inflammatory mediators in neutrophils (Lee et al., 2005) .", [["granules", "ANATOMY", 96, 104], ["neutrophils", "ANATOMY", 142, 153], ["S100A11", "GENE_OR_GENE_PRODUCT", 32, 39], ["HSP90AB1", "GENE_OR_GENE_PRODUCT", 41, 49], ["EEF1A1", "GENE_OR_GENE_PRODUCT", 60, 66], ["granules", "CELLULAR_COMPONENT", 96, 104], ["neutrophils", "CELL", 142, 153], ["S100A11", "PROTEIN", 32, 39], ["HSP90AB1", "PROTEIN", 41, 49], ["EEF1A1", "PROTEIN", 60, 66], ["inflammatory mediators", "PROTEIN", 116, 138], ["neutrophils", "CELL_TYPE", 142, 153], ["S100A11", "TEST", 32, 39], ["HSP90AB1", "TEST", 41, 49], ["EEF1A1", "TEST", 60, 66], ["inflammatory mediators in neutrophils", "PROBLEM", 116, 153], ["granules", "OBSERVATION_MODIFIER", 96, 104], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["neutrophils", "ANATOMY", 142, 153]]], ["All these genes, with the exception of TXNIP and S100A11, are also highly expressed in the arterial tissue.", [["arterial tissue", "ANATOMY", 91, 106], ["TXNIP", "GENE_OR_GENE_PRODUCT", 39, 44], ["S100A11", "GENE_OR_GENE_PRODUCT", 49, 56], ["arterial tissue", "TISSUE", 91, 106], ["TXNIP", "PROTEIN", 39, 44], ["S100A11", "PROTEIN", 49, 56], ["TXNIP", "TEST", 39, 44], ["genes", "OBSERVATION", 10, 15], ["TXNIP", "OBSERVATION", 39, 44], ["arterial tissue", "ANATOMY", 91, 106]]], ["We highlight the presence in our analysis of the HSP90AB1, a known chaperone that facilitates the maturation of a wide range of proteins and its attenuation has been related to idiopathic pulmonary fibrosis and cystic fibrosis (Haase and Fitze, 2015; Wang and Ni, 2016 ).", [["pulmonary", "ANATOMY", 188, 197], ["cystic", "ANATOMY", 211, 217], ["idiopathic pulmonary fibrosis", "DISEASE", 177, 206], ["cystic fibrosis", "DISEASE", 211, 226], ["HSP90AB1", "GENE_OR_GENE_PRODUCT", 49, 57], ["pulmonary", "ORGAN", 188, 197], ["HSP90AB1", "PROTEIN", 49, 57], ["the HSP90AB1", "TEST", 45, 57], ["idiopathic pulmonary fibrosis", "PROBLEM", 177, 206], ["cystic fibrosis", "PROBLEM", 211, 226], ["related to", "UNCERTAINTY", 166, 176], ["idiopathic", "OBSERVATION_MODIFIER", 177, 187], ["pulmonary", "ANATOMY", 188, 197], ["fibrosis", "OBSERVATION", 198, 206], ["cystic", "OBSERVATION_MODIFIER", 211, 217], ["fibrosis", "OBSERVATION", 218, 226]]], ["Our analysis also shows a translation decrease in A2M, a plasmatic protein highly expressed in lung and artery that inhibits a broad spectrum of proteases, including trypsin, thrombin, and collagenase (Cater et al., 2019) .", [["lung", "ANATOMY", 95, 99], ["artery", "ANATOMY", 104, 110], ["A2M", "GENE_OR_GENE_PRODUCT", 50, 53], ["lung", "ORGAN", 95, 99], ["artery", "MULTI-TISSUE_STRUCTURE", 104, 110], ["trypsin", "GENE_OR_GENE_PRODUCT", 166, 173], ["thrombin", "GENE_OR_GENE_PRODUCT", 175, 183], ["collagenase", "GENE_OR_GENE_PRODUCT", 189, 200], ["A2M", "PROTEIN", 50, 53], ["plasmatic protein", "PROTEIN", 57, 74], ["proteases", "PROTEIN", 145, 154], ["trypsin", "PROTEIN", 166, 173], ["thrombin", "PROTEIN", 175, 183], ["collagenase", "PROTEIN", 189, 200], ["Our analysis", "TEST", 0, 12], ["a translation decrease in A2M", "PROBLEM", 24, 53], ["a plasmatic protein", "TEST", 55, 74], ["a broad spectrum of proteases", "PROBLEM", 125, 154], ["trypsin", "TREATMENT", 166, 173], ["thrombin", "TREATMENT", 175, 183], ["collagenase", "TREATMENT", 189, 200], ["decrease", "OBSERVATION_MODIFIER", 38, 46], ["lung", "ANATOMY", 95, 99], ["artery", "ANATOMY", 104, 110]]], ["A recent study confirms our prediction, A2M level in sera from COVID-19 patients is significantly lower than in healthy subjects (Shen et al., 2020) .", [["sera", "ANATOMY", 53, 57], ["A2M", "GENE_OR_GENE_PRODUCT", 40, 43], ["sera", "ORGANISM_SUBSTANCE", 53, 57], ["patients", "ORGANISM", 72, 80], ["A2M", "PROTEIN", 40, 43], ["patients", "SPECIES", 72, 80], ["A recent study", "TEST", 0, 14], ["our prediction", "TEST", 24, 38], ["A2M level", "TEST", 40, 49], ["sera", "TEST", 53, 57], ["COVID", "TEST", 63, 68], ["significantly", "OBSERVATION_MODIFIER", 84, 97], ["lower", "OBSERVATION_MODIFIER", 98, 103]]], ["Furthermore, A2M has a key role in regulating inflammatory processes because is able to bind to proinflammatory ligands (Feige et al., 1996) .", [["A2M", "CHEMICAL", 13, 16], ["A2M", "GENE_OR_GENE_PRODUCT", 13, 16], ["A2M", "PROTEIN", 13, 16], ["regulating inflammatory processes", "PROBLEM", 35, 68], ["inflammatory", "OBSERVATION", 46, 58]]], ["This is particularly relevant in the context of the COVID-19-derived cytokine storm.RESULTSIn addition, we have also identified two genes (SAT1 and MGP) belonging to the pathway of endothelial cell calcification regulated by NOTCH1 (White et al., 2015) .", [["endothelial cell", "ANATOMY", 181, 197], ["calcification", "DISEASE", 198, 211], ["SAT1", "GENE_OR_GENE_PRODUCT", 139, 143], ["MGP", "GENE_OR_GENE_PRODUCT", 148, 151], ["endothelial cell", "CELL", 181, 197], ["NOTCH1", "GENE_OR_GENE_PRODUCT", 225, 231], ["COVID-19", "DNA", 52, 60], ["cytokine", "PROTEIN", 69, 77], ["SAT1", "DNA", 139, 143], ["MGP", "DNA", 148, 151], ["NOTCH1", "PROTEIN", 225, 231], ["the COVID", "TEST", 48, 57], ["endothelial cell calcification", "PROBLEM", 181, 211], ["cytokine storm", "OBSERVATION", 69, 83], ["endothelial cell calcification", "OBSERVATION", 181, 211]]], ["This finding acquires special relevance in the context of the acute lung injury (ALI) observed in many infected patients (Huang et al., 2020) .", [["lung", "ANATOMY", 68, 72], ["acute lung injury", "DISEASE", 62, 79], ["ALI", "DISEASE", 81, 84], ["lung", "ORGAN", 68, 72], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["the acute lung injury", "PROBLEM", 58, 79], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["lung", "ANATOMY", 68, 72], ["injury", "OBSERVATION", 73, 79], ["many", "OBSERVATION_MODIFIER", 98, 102], ["infected", "OBSERVATION_MODIFIER", 103, 111]]], ["The first gene SAT1 catalyzes the acetylation of polyamines (spermidine and spermine) and carries it out of the cell.", [["cell", "ANATOMY", 112, 116], ["spermidine", "CHEMICAL", 61, 71], ["spermine", "CHEMICAL", 76, 84], ["polyamines", "CHEMICAL", 49, 59], ["spermidine", "CHEMICAL", 61, 71], ["spermine", "CHEMICAL", 76, 84], ["SAT1", "GENE_OR_GENE_PRODUCT", 15, 19], ["polyamines", "SIMPLE_CHEMICAL", 49, 59], ["spermidine", "SIMPLE_CHEMICAL", 61, 71], ["spermine", "SIMPLE_CHEMICAL", 76, 84], ["cell", "CELL", 112, 116], ["SAT1", "DNA", 15, 19], ["polyamines (spermidine and spermine)", "TREATMENT", 49, 85], ["cell", "ANATOMY", 112, 116]]], ["The polyamine excess is a prominent source of oxidative stress that can increase inflammatory response (Hussain et al., 2017) .", [["polyamine", "CHEMICAL", 4, 13], ["polyamine", "CHEMICAL", 4, 13], ["polyamine", "SIMPLE_CHEMICAL", 4, 13], ["The polyamine excess", "PROBLEM", 0, 20], ["oxidative stress", "PROBLEM", 46, 62], ["inflammatory response", "PROBLEM", 81, 102], ["polyamine excess", "OBSERVATION", 4, 20], ["prominent", "OBSERVATION_MODIFIER", 26, 35], ["oxidative stress", "OBSERVATION", 46, 62], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93]]], ["Polyamines have also been connected with the immune system (P\u00e9rez-Cano et al., 2003) .", [["Polyamines", "CHEMICAL", 0, 10], ["Polyamines", "SIMPLE_CHEMICAL", 0, 10], ["Polyamines", "TREATMENT", 0, 10]]], ["On the other hand, the MGP gene encodes the matrix gla protein, which is also highly expressed in all vasculatures.", [["vasculatures", "ANATOMY", 102, 114], ["MGP", "GENE_OR_GENE_PRODUCT", 23, 26], ["matrix gla", "GENE_OR_GENE_PRODUCT", 44, 54], ["MGP gene", "DNA", 23, 31], ["matrix gla protein", "PROTEIN", 44, 62], ["the matrix gla protein", "TEST", 40, 62], ["all", "ANATOMY_MODIFIER", 98, 101], ["vasculatures", "ANATOMY", 102, 114]]], ["Recent studies suggest that MGP downregulates the tissue calcification by sequestering bone morphogenetic proteins (White et al., 2015) .", [["tissue", "ANATOMY", 50, 56], ["bone", "ANATOMY", 87, 91], ["calcification", "DISEASE", 57, 70], ["MGP", "GENE_OR_GENE_PRODUCT", 28, 31], ["tissue", "TISSUE", 50, 56], ["bone", "TISSUE", 87, 91], ["MGP", "PROTEIN", 28, 31], ["bone morphogenetic proteins", "PROTEIN", 87, 114], ["Recent studies", "TEST", 0, 14], ["MGP downregulates the tissue calcification", "PROBLEM", 28, 70], ["sequestering bone morphogenetic proteins", "PROBLEM", 74, 114], ["tissue", "OBSERVATION_MODIFIER", 50, 56], ["calcification", "OBSERVATION", 57, 70], ["bone", "ANATOMY", 87, 91]]], ["Mutations in this gene cause Keutel syndrome, which is characterized by peripheral pulmonary stenosis, abnormal cartilage calcification, and skin rashes (Munroe et al., 1999) .RESULTSAnother interesting protein predicted to be downregulated during the infection in lung and arterial tissues is SPARC-like 1 (SPARCL-1), also known as Hevin, commonly associated with regulation of cell migration and modulation of extracellular matrix proteins (Girard and Springer, 1996) , and it has been shown to be involved in lymphocyte transendothelial migration through high endothelial venules (Girard and Springer, 1995) .", [["pulmonary", "ANATOMY", 83, 92], ["cartilage", "ANATOMY", 112, 121], ["skin", "ANATOMY", 141, 145], ["lung", "ANATOMY", 265, 269], ["arterial tissues", "ANATOMY", 274, 290], ["cell", "ANATOMY", 379, 383], ["extracellular matrix", "ANATOMY", 412, 432], ["lymphocyte transendothelial", "ANATOMY", 512, 539], ["endothelial venules", "ANATOMY", 563, 582], ["Keutel syndrome", "DISEASE", 29, 44], ["peripheral pulmonary stenosis", "DISEASE", 72, 101], ["abnormal cartilage calcification", "DISEASE", 103, 135], ["skin rashes", "DISEASE", 141, 152], ["infection", "DISEASE", 252, 261], ["pulmonary", "ORGAN", 83, 92], ["cartilage", "TISSUE", 112, 121], ["skin", "ORGAN", 141, 145], ["lung", "ORGAN", 265, 269], ["arterial tissues", "TISSUE", 274, 290], ["SPARC-like 1", "GENE_OR_GENE_PRODUCT", 294, 306], ["SPARCL-1", "GENE_OR_GENE_PRODUCT", 308, 316], ["Hevin", "GENE_OR_GENE_PRODUCT", 333, 338], ["cell", "CELL", 379, 383], ["extracellular matrix", "CELLULAR_COMPONENT", 412, 432], ["lymphocyte", "CELL", 512, 522], ["transendothelial", "CELL", 523, 539], ["endothelial venules", "TISSUE", 563, 582], ["SPARC", "PROTEIN", 294, 299], ["SPARCL", "PROTEIN", 308, 314], ["Hevin", "PROTEIN", 333, 338], ["extracellular matrix proteins", "PROTEIN", 412, 441], ["endothelial venules", "CELL_TYPE", 563, 582], ["Mutations", "PROBLEM", 0, 9], ["Keutel syndrome", "PROBLEM", 29, 44], ["peripheral pulmonary stenosis", "PROBLEM", 72, 101], ["abnormal cartilage calcification", "PROBLEM", 103, 135], ["skin rashes", "PROBLEM", 141, 152], ["interesting protein", "PROBLEM", 191, 210], ["the infection in lung and arterial tissues", "PROBLEM", 248, 290], ["SPARC", "TEST", 294, 299], ["SPARCL", "TEST", 308, 314], ["cell migration", "TREATMENT", 379, 393], ["extracellular matrix proteins", "PROBLEM", 412, 441], ["lymphocyte transendothelial migration", "TREATMENT", 512, 549], ["Keutel syndrome", "OBSERVATION", 29, 44], ["peripheral", "ANATOMY_MODIFIER", 72, 82], ["pulmonary", "ANATOMY", 83, 92], ["stenosis", "OBSERVATION", 93, 101], ["abnormal", "OBSERVATION_MODIFIER", 103, 111], ["cartilage", "OBSERVATION_MODIFIER", 112, 121], ["calcification", "OBSERVATION", 122, 135], ["skin", "ANATOMY", 141, 145], ["rashes", "OBSERVATION", 146, 152], ["infection", "OBSERVATION", 252, 261], ["lung", "ANATOMY", 265, 269], ["arterial tissues", "ANATOMY", 274, 290], ["SPARC", "OBSERVATION", 294, 299], ["cell migration", "OBSERVATION", 379, 393], ["lymphocyte transendothelial migration", "OBSERVATION", 512, 549], ["high endothelial venules", "OBSERVATION", 558, 582]]], ["In this context, it is important to mention that clinical studies over patients that suffer several cases of COVID-19 document a dysregulation of immune response related particularly to a lower lymphocytes count (Huang et al., 2020) .", [["lymphocytes", "ANATOMY", 194, 205], ["COVID-19", "CHEMICAL", 109, 117], ["patients", "ORGANISM", 71, 79], ["lymphocytes", "CELL", 194, 205], ["lymphocytes", "CELL_TYPE", 194, 205], ["patients", "SPECIES", 71, 79], ["clinical studies", "TEST", 49, 65], ["COVID", "TEST", 109, 114], ["a dysregulation of immune response", "PROBLEM", 127, 161], ["a lower lymphocytes count", "PROBLEM", 186, 211], ["lower lymphocytes", "ANATOMY", 188, 205]]], ["In addition, our analysis reveals a translational rate decay of fibronectin (FN1), a master organizer of extracellular matrices that mediates cellular interactions playing important roles in cell adhesion, hemostasis, and thrombosis (Pankov and Yamada, 2002; Wang and Ni, 2016) .", [["extracellular matrices", "ANATOMY", 105, 127], ["cellular", "ANATOMY", 142, 150], ["cell", "ANATOMY", 191, 195], ["thrombosis", "DISEASE", 222, 232], ["fibronectin", "GENE_OR_GENE_PRODUCT", 64, 75], ["FN1", "GENE_OR_GENE_PRODUCT", 77, 80], ["extracellular matrices", "CELLULAR_COMPONENT", 105, 127], ["cellular", "CELL", 142, 150], ["cell", "CELL", 191, 195], ["fibronectin", "PROTEIN", 64, 75], ["FN1", "PROTEIN", 77, 80], ["our analysis", "TEST", 13, 25], ["cell adhesion", "TREATMENT", 191, 204], ["hemostasis", "TREATMENT", 206, 216], ["thrombosis", "PROBLEM", 222, 232], ["extracellular matrices", "OBSERVATION", 105, 127], ["cellular interactions", "OBSERVATION", 142, 163], ["cell adhesion", "OBSERVATION", 191, 204], ["thrombosis", "OBSERVATION", 222, 232]]], ["This prediction is in agreement with previous data showing that cells infected with SARS-CoV undergo downregulation in fibronectin expression (Surjit et al., 2004) .DISCUSSIONThe viral infection of human cells triggers an ensemble of host processes based on the interferons that interfere with viral replication.", [["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 204, 209], ["SARS", "DISEASE", 84, 88], ["viral infection", "DISEASE", 179, 194], ["cells", "CELL", 64, 69], ["SARS-CoV", "ORGANISM", 84, 92], ["fibronectin", "GENE_OR_GENE_PRODUCT", 119, 130], ["human", "ORGANISM", 198, 203], ["cells", "CELL", 204, 209], ["fibronectin", "PROTEIN", 119, 130], ["human cells", "CELL_TYPE", 198, 209], ["interferons", "PROTEIN", 262, 273], ["human", "SPECIES", 198, 203], ["SARS-CoV", "SPECIES", 84, 92], ["human", "SPECIES", 198, 203], ["previous data", "TEST", 37, 50], ["cells infected", "PROBLEM", 64, 78], ["SARS", "PROBLEM", 84, 88], ["downregulation in fibronectin expression", "TREATMENT", 101, 141], ["The viral infection of human cells", "PROBLEM", 175, 209], ["the interferons", "TREATMENT", 258, 273], ["viral replication", "TREATMENT", 294, 311], ["fibronectin expression", "OBSERVATION_MODIFIER", 119, 141], ["viral", "OBSERVATION_MODIFIER", 179, 184], ["infection", "OBSERVATION", 185, 194], ["human cells", "OBSERVATION", 198, 209]]], ["These processes have co-evolved with the viral response to the host defense, and the virus counteracts these processes through a diversity of immuno-modulatory mechanisms.", [["the virus", "PROBLEM", 81, 90], ["immuno-modulatory mechanisms", "PROBLEM", 142, 170], ["host defense", "OBSERVATION", 63, 75]]], ["For example, NS1 protein plays a central role in the influenza infection by suppressing the host IFNs response.", [["influenza infection", "DISEASE", 53, 72], ["NS1", "GENE_OR_GENE_PRODUCT", 13, 16], ["IFNs", "GENE_OR_GENE_PRODUCT", 97, 101], ["NS1 protein", "PROTEIN", 13, 24], ["IFNs", "PROTEIN", 97, 101], ["NS1 protein", "PROBLEM", 13, 24], ["the influenza infection", "PROBLEM", 49, 72], ["NS1 protein", "OBSERVATION", 13, 24], ["central", "OBSERVATION_MODIFIER", 33, 40], ["influenza", "OBSERVATION_MODIFIER", 53, 62], ["infection", "OBSERVATION", 63, 72]]], ["Recent results suggest that NS1 protein can hamper the host gene expression at the translational level by obstructing the mRNA entrance tunnel of ribosomes (Thoms et al., 2020) .", [["ribosomes", "ANATOMY", 146, 155], ["NS1", "GENE_OR_GENE_PRODUCT", 28, 31], ["ribosomes", "CELLULAR_COMPONENT", 146, 155], ["NS1 protein", "PROTEIN", 28, 39], ["NS1 protein", "PROBLEM", 28, 39], ["NS1 protein", "OBSERVATION", 28, 39], ["obstructing", "OBSERVATION", 106, 117], ["mRNA", "OBSERVATION_MODIFIER", 122, 126], ["entrance tunnel", "OBSERVATION", 127, 142]]], ["Furthermore, the N protein of porcine reproductive and respiratory syndrome virus impairs the IFN transcription by acting over the TXK, which together with the EEF1A1 and PARP1 form the trimolecular complex that binds to the IFN\u03b3 gene promoter (Maruyama et al., 2007; Kenney and Meng, 2015) .", [["porcine reproductive and respiratory syndrome", "DISEASE", 30, 75], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 30, 81], ["IFN", "GENE_OR_GENE_PRODUCT", 94, 97], ["TXK", "GENE_OR_GENE_PRODUCT", 131, 134], ["EEF1A1", "GENE_OR_GENE_PRODUCT", 160, 166], ["PARP1", "GENE_OR_GENE_PRODUCT", 171, 176], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 225, 229], ["N protein", "PROTEIN", 17, 26], ["IFN", "PROTEIN", 94, 97], ["TXK", "PROTEIN", 131, 134], ["EEF1A1", "PROTEIN", 160, 166], ["PARP1", "PROTEIN", 171, 176], ["trimolecular complex", "PROTEIN", 186, 206], ["IFN\u03b3 gene promoter", "DNA", 225, 243], ["porcine reproductive", "PROBLEM", 30, 50], ["respiratory syndrome virus", "PROBLEM", 55, 81], ["the IFN transcription", "TREATMENT", 90, 111], ["PARP1", "TREATMENT", 171, 176], ["respiratory syndrome", "OBSERVATION", 55, 75]]], ["Hemagglutinin of IAVs has been shown to facilitate IFNAR ubiquitination and degradation, reducing the levels of IFNAR, and thus suppressing the expression of IFN-stimulated antiviral proteins (Xia et al., 2016) .", [["Hemagglutinin", "CHEMICAL", 0, 13], ["IAVs", "CHEMICAL", 17, 21], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 13], ["IAVs", "GENE_OR_GENE_PRODUCT", 17, 21], ["IFNAR", "GENE_OR_GENE_PRODUCT", 51, 56], ["IFNAR", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN", "GENE_OR_GENE_PRODUCT", 158, 161], ["Hemagglutinin", "PROTEIN", 0, 13], ["IAVs", "PROTEIN", 17, 21], ["IFNAR", "PROTEIN", 51, 56], ["IFNAR", "PROTEIN", 112, 117], ["IFN-stimulated antiviral proteins", "PROTEIN", 158, 191], ["Hemagglutinin of IAVs", "TREATMENT", 0, 21], ["IFNAR ubiquitination", "PROBLEM", 51, 71], ["IFN-stimulated antiviral proteins", "TREATMENT", 158, 191], ["IAVs", "OBSERVATION", 17, 21], ["IFNAR ubiquitination", "OBSERVATION", 51, 71]]], ["These examples illustrate the action of viral dedicated factors that downregulate the transcription of IFNs.", [["IFNs", "GENE_OR_GENE_PRODUCT", 103, 107], ["viral dedicated factors", "PROTEIN", 40, 63], ["IFNs", "PROTEIN", 103, 107], ["viral dedicated factors", "PROBLEM", 40, 63]]], ["Up to the present, no dedicated factor with analog function has been identified in SARS-CoV and SARS-CoV-2.", [["SARS", "DISEASE", 83, 87], ["SARS", "DISEASE", 96, 100], ["SARS-CoV", "ORGANISM", 83, 91], ["SARS-CoV-2", "ORGANISM", 96, 106], ["SARS-CoV", "SPECIES", 83, 91], ["SARS-CoV", "SPECIES", 96, 104], ["analog function", "TEST", 44, 59], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104]]], ["However, a recent report found a significant lack of IFN type I and III at the transcriptional level in human alveolar adenocarcinoma cells (Blanco-Melo et al., 2020) .", [["alveolar adenocarcinoma cells", "ANATOMY", 110, 139], ["alveolar adenocarcinoma", "DISEASE", 110, 133], ["IFN type I", "GENE_OR_GENE_PRODUCT", 53, 63], ["III", "GENE_OR_GENE_PRODUCT", 68, 71], ["human", "ORGANISM", 104, 109], ["alveolar adenocarcinoma cells", "CELL", 110, 139], ["IFN type I and III", "PROTEIN", 53, 71], ["human alveolar adenocarcinoma cells", "CELL_TYPE", 104, 139], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["IFN type I and III", "PROBLEM", 53, 71], ["human alveolar adenocarcinoma cells", "PROBLEM", 104, 139], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["human", "ANATOMY", 104, 109], ["alveolar", "ANATOMY_MODIFIER", 110, 118], ["adenocarcinoma cells", "OBSERVATION", 119, 139]]], ["On the other hand, a marked upregulation of inflammatory mediators at the protein level (CXCL10, CCL2, IFN-\u03b1, and \u03b3 ) has been observed in patients with SARS-CoV without a significant amount of specific antibodies (Cameron et al., 2007) .", [["SARS-CoV", "DISEASE", 153, 161], ["CXCL10", "GENE_OR_GENE_PRODUCT", 89, 95], ["CCL2", "GENE_OR_GENE_PRODUCT", 97, 101], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 103, 108], ["\u03b3", "GENE_OR_GENE_PRODUCT", 114, 115], ["patients", "ORGANISM", 139, 147], ["SARS-CoV", "ORGANISM", 153, 161], ["inflammatory mediators", "PROTEIN", 44, 66], ["CXCL10", "PROTEIN", 89, 95], ["CCL2", "PROTEIN", 97, 101], ["IFN", "PROTEIN", 103, 106], ["\u03b1", "PROTEIN", 107, 108], ["\u03b3", "PROTEIN", 114, 115], ["specific antibodies", "PROTEIN", 194, 213], ["patients", "SPECIES", 139, 147], ["SARS-CoV", "SPECIES", 153, 161], ["a marked upregulation of inflammatory mediators", "PROBLEM", 19, 66], ["the protein level", "TEST", 70, 87], ["CXCL10", "TEST", 89, 95], ["CCL2", "TEST", 97, 101], ["IFN", "TEST", 103, 106], ["SARS", "PROBLEM", 153, 157], ["marked", "OBSERVATION_MODIFIER", 21, 27], ["upregulation", "OBSERVATION", 28, 40], ["inflammatory", "OBSERVATION", 44, 56]]], ["Several cases of absence of protective immunity due to previous infection seem to indicate a similar landscape for COVID-19.", [["infection", "DISEASE", 64, 73], ["protective immunity", "TREATMENT", 28, 47], ["previous infection", "PROBLEM", 55, 73], ["COVID", "TEST", 115, 120], ["infection", "OBSERVATION", 64, 73]]], ["Until now, the manner in which some patients fail to develop adaptive immunity is yet to be elucidated.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["adaptive immunity", "TREATMENT", 61, 78]]], ["As mentioned in the Results section, the decreased translation of B2M could be related to this last observation since is a crucial factor for the stable presentation of antigens derived from virus or tumor proteins; these antigens are recognized by cytotoxic T cells that eventually eliminate the target cell stimulating apoptosis to prevent systemic dissemination of the disease (Hulpke and Tamp\u00e9, 2013) .DISCUSSIONMGP is also expressed at high levels in heart, kidney, and lung which is particularly interesting in the context of several comorbidities and collateral effects observed in the COVID-19 patients (Nikolich-Zugich et al., 2020) .", [["tumor", "ANATOMY", 200, 205], ["cytotoxic T cells", "ANATOMY", 249, 266], ["cell", "ANATOMY", 304, 308], ["heart", "ANATOMY", 456, 461], ["kidney", "ANATOMY", 463, 469], ["lung", "ANATOMY", 475, 479], ["collateral", "ANATOMY", 558, 568], ["tumor", "DISEASE", 200, 205], ["B2M", "GENE_OR_GENE_PRODUCT", 66, 69], ["tumor", "CANCER", 200, 205], ["cytotoxic T cells", "CELL", 249, 266], ["cell", "CELL", 304, 308], ["heart", "ORGAN", 456, 461], ["kidney", "ORGAN", 463, 469], ["lung", "ORGAN", 475, 479], ["patients", "ORGANISM", 602, 610], ["B2M", "PROTEIN", 66, 69], ["antigens", "PROTEIN", 169, 177], ["tumor proteins", "PROTEIN", 200, 214], ["antigens", "PROTEIN", 222, 230], ["cytotoxic T cells", "CELL_TYPE", 249, 266], ["DISCUSSIONMGP", "PROTEIN", 406, 419], ["patients", "SPECIES", 602, 610], ["the decreased translation of B2M", "PROBLEM", 37, 69], ["a crucial factor", "PROBLEM", 121, 137], ["antigens", "PROBLEM", 169, 177], ["virus", "PROBLEM", 191, 196], ["tumor proteins", "PROBLEM", 200, 214], ["cytotoxic T cells", "PROBLEM", 249, 266], ["the target cell stimulating apoptosis", "PROBLEM", 293, 330], ["systemic dissemination of the disease", "PROBLEM", 342, 379], ["high levels in heart, kidney, and lung", "PROBLEM", 441, 479], ["several comorbidities", "PROBLEM", 532, 553], ["collateral effects", "PROBLEM", 558, 576], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["B2M", "OBSERVATION", 66, 69], ["stable", "OBSERVATION_MODIFIER", 146, 152], ["tumor", "OBSERVATION", 200, 205], ["target cell stimulating apoptosis", "OBSERVATION", 297, 330], ["systemic", "OBSERVATION_MODIFIER", 342, 350], ["dissemination", "OBSERVATION", 351, 364], ["heart", "ANATOMY", 456, 461], ["kidney", "ANATOMY", 463, 469], ["lung", "ANATOMY", 475, 479], ["collateral effects", "OBSERVATION", 558, 576]]], ["For example, skin rashes were recently reported as a new symptom of COVID-19 and the authors postulate that recognizing rashes is important to identify new and earlier COVID-19, cases (Bataille et al., 2020) .", [["skin", "ANATOMY", 13, 17], ["skin rashes", "DISEASE", 13, 24], ["rashes", "DISEASE", 120, 126], ["skin", "ORGAN", 13, 17], ["rashes", "PATHOLOGICAL_FORMATION", 120, 126], ["skin rashes", "PROBLEM", 13, 24], ["COVID", "TEST", 68, 73], ["rashes", "PROBLEM", 120, 126], ["skin", "ANATOMY", 13, 17], ["rashes", "OBSERVATION", 18, 24]]], ["In this context, we highlight that permanent skin rashes were reported as a characteristic of the Keutel syndrome, and mutations in the MGP gene were reported as a crucial factor in this syndrome (Munroe et al., 1999; Khosroshahi et al., 2014) .", [["skin", "ANATOMY", 45, 49], ["skin rashes", "DISEASE", 45, 56], ["Keutel syndrome", "DISEASE", 98, 113], ["skin", "ORGAN", 45, 49], ["MGP", "GENE_OR_GENE_PRODUCT", 136, 139], ["MGP gene", "DNA", 136, 144], ["permanent skin rashes", "PROBLEM", 35, 56], ["the Keutel syndrome", "PROBLEM", 94, 113], ["mutations in the MGP gene", "PROBLEM", 119, 144], ["this syndrome", "PROBLEM", 182, 195], ["skin", "ANATOMY", 45, 49], ["rashes", "OBSERVATION", 50, 56], ["Keutel syndrome", "OBSERVATION", 98, 113]]], ["Summing up, if the depletion of a selected set of tRNA, induced by virus replication, affects the expression level or the co-translation folding of these proteins, one could expect the emergence of several systemic disorders.CONCLUSIONCodon usage bias is thought to have significant effects on translation rate, where rare codons are assumed to be translated more slowly than common codons (Piovesan et al., 2013) .", [["tRNA", "TREATMENT", 50, 54], ["virus replication", "PROBLEM", 67, 84], ["the expression level", "PROBLEM", 94, 114], ["several systemic disorders.CONCLUSIONCodon usage bias", "PROBLEM", 198, 251], ["translation rate", "TEST", 294, 310], ["rare codons", "PROBLEM", 318, 329]]], ["It is assumed that rare and common codons are defined by usage rates of highly expressed genes.", [["rare and common codons", "PROBLEM", 19, 41], ["common codons", "OBSERVATION", 28, 41]]], ["However, whether the codon composition of viral ORFome can affect the translation rate of host genes has not been thoroughly explored yet.", [["ORFome", "GENE_OR_GENE_PRODUCT", 48, 54], ["viral ORFome", "PROTEIN", 42, 54], ["host genes", "DNA", 90, 100]]], ["Here, we have shown that the synthesis of the proteins associated with highly expressed genes, and with similar codon usage to the one of the virus, appears to be downregulated.", [["the synthesis of the proteins", "PROBLEM", 25, 54], ["the virus", "PROBLEM", 138, 147], ["appears to be", "UNCERTAINTY", 149, 162], ["downregulated", "OBSERVATION", 163, 176]]], ["This finding is in agreement with recent observations in totivirusinfected yeast (Chen et al., 2020) .", [["yeast", "SPECIES", 75, 80], ["yeast", "SPECIES", 75, 80]]], ["Following this idea, we determined which genes in lung could be affected by the viral replication.", [["lung", "ANATOMY", 50, 54], ["lung", "ORGAN", 50, 54], ["the viral replication", "TREATMENT", 76, 97], ["lung", "ANATOMY", 50, 54], ["viral replication", "OBSERVATION", 80, 97]]], ["A functional analysis of these genes reveals that they could be related to collateral effects observed in COVID-19 patients (Huang et al., 2020) .", [["collateral", "ANATOMY", 75, 85], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["A functional analysis", "TEST", 0, 21], ["collateral effects", "PROBLEM", 75, 93], ["could be related to", "UNCERTAINTY", 55, 74], ["collateral effects", "OBSERVATION", 75, 93]]], ["Further studies are mandatory to corroborate or discard the putative relationship established here.CONCLUSIONOne of the main obstacles in the recent development of vaccines has been the finding of increased infectivity observed to occur after immunizations with whole virus vaccines or complete spike protein vaccines.", [["Further studies", "TEST", 0, 15], ["vaccines", "TREATMENT", 164, 172], ["increased infectivity", "PROBLEM", 197, 218], ["immunizations", "TREATMENT", 243, 256], ["whole virus vaccines", "TREATMENT", 262, 282], ["complete spike protein vaccines", "TREATMENT", 286, 317], ["main", "OBSERVATION_MODIFIER", 120, 124], ["obstacles", "OBSERVATION", 125, 134], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["infectivity", "OBSERVATION", 207, 218]]], ["This phenomenon has been observed both in vaccines against SARS coronavirus and in respiratory syncytial virus.", [["SARS coronavirus", "DISEASE", 59, 75], ["respiratory syncytial virus", "DISEASE", 83, 110], ["SARS coronavirus", "ORGANISM", 59, 75], ["respiratory syncytial virus", "ORGANISM", 83, 110], ["respiratory syncytial virus", "SPECIES", 83, 110], ["SARS coronavirus", "SPECIES", 59, 75], ["respiratory syncytial virus", "SPECIES", 83, 110], ["vaccines", "TREATMENT", 42, 50], ["SARS coronavirus", "PROBLEM", 59, 75], ["respiratory syncytial virus", "PROBLEM", 83, 110], ["respiratory syncytial virus", "OBSERVATION", 83, 110]]], ["However, just as the virus regulates the translation of the host by its codon usage, the biotechnological manipulation of the frequency of codons could be used to design attenuated viruses.", [["codons", "TREATMENT", 139, 145], ["attenuated viruses", "PROBLEM", 170, 188], ["viruses", "OBSERVATION", 181, 188]]], ["In this sense, other vaccine strategy has been recently assayed, focusing on altering the codon-pair usage without affecting protein sequence.", [["other vaccine strategy", "TREATMENT", 15, 37], ["affecting protein sequence", "PROBLEM", 115, 141]]], ["This codon deoptimization strategy has reduced virus replication (Coleman et al., 2008; Le Nouen et al., 2014) .", [["This codon deoptimization strategy", "TREATMENT", 0, 34]]], ["We believe that our results shed light on how codon use could affect virus attenuation and would help decrease the damaging side effect, providing an exciting opportunity for live-attenuated vaccine development.DATA AVAILABILITY STATEMENTPublicly available datasets were analyzed in this study.", [["virus attenuation", "PROBLEM", 69, 86], ["the damaging side effect", "PROBLEM", 111, 135], ["live-attenuated vaccine development", "TREATMENT", 175, 210], ["datasets", "TEST", 257, 265], ["this study", "TEST", 283, 293]]], ["ID=PXD017710.AUTHOR CONTRIBUTIONSLD designed the experiments.", [["PXD017710", "CHEMICAL", 3, 12], ["PXD017710", "CHEMICAL", 3, 12]]]], "eea2cbd05f11c76f9ce3cdb9e5d2c156dfe506a2": [["Usually characterized as a transition from \"international\" to \"global\" health, this shift has been accompanied by epidemiological, organizational, geopolitical and financial transformations.", [["epidemiological, organizational, geopolitical and financial transformations", "PROBLEM", 114, 189], ["financial transformations", "OBSERVATION", 164, 189]]], ["Even though global health has emerged as the dominant term for attempts to address matters of health and disease on a transnational scale, how it differs from earlier designations such as international health or tropical medicine remains underspecified (Anderson 2014; Banta 2001; Brown et al. 2006; Fried et al. 2010; Kleinman 2010; Koplan et al. 2009; Lakoff 2010; McGoey et al. 2011) .", [["disease", "PROBLEM", 105, 112], ["a transnational scale", "TREATMENT", 116, 137]]], ["Scholars have observed a number of features that have accompanied the rise of global health: the declining role of the World Health Organization (WHO) dating from the budget freezes of the 1980s, the relative ascendance of the World Bank in world health affairs, the proliferation of public private partnerships, Bill Gates-style philanthrocapitalism, and an emphasis on health threats that transcend national boundaries, i.e. HIV/AIDs, SARS, pandemic influenza and, more recently, the ebola virus (Brown et al. 2006; Chorev 2012; Kenny 2015; Lakoff and Collier 2008; McCarthy 2002; McCoy et al. 2009; Ruger 2005; Thomas and Weber 2004) .", [["philanthrocapitalism", "DISEASE", 330, 350], ["HIV/AIDs", "DISEASE", 427, 435], ["SARS", "DISEASE", 437, 441], ["influenza", "DISEASE", 452, 461], ["ebola virus", "ORGANISM", 486, 497], ["HIV", "SPECIES", 427, 430], ["ebola virus", "SPECIES", 486, 497], ["HIV/AIDs", "PROBLEM", 427, 435], ["SARS", "PROBLEM", 437, 441], ["pandemic influenza", "PROBLEM", 443, 461]]], ["In this paper I identify a less frequently observed feature: the rise of non-communicable diseases (NCDs) as a global health concern.", [["non-communicable diseases", "DISEASE", 73, 98], ["NCDs", "DISEASE", 100, 104], ["non-communicable diseases", "PROBLEM", 73, 98]]], ["NCDs, also known as \"chronic\" or \"lifestyle\" diseases, include conditions such as cardiovascular disease, cancer, respiratory disease and diabetes and share four common risk factors: tobacco use, physical inactivity, alcohol consumption and unhealthy diet.", [["cardiovascular", "ANATOMY", 82, 96], ["cancer", "ANATOMY", 106, 112], ["respiratory", "ANATOMY", 114, 125], ["NCDs", "DISEASE", 0, 4], ["cardiovascular disease", "DISEASE", 82, 104], ["cancer", "DISEASE", 106, 112], ["respiratory disease", "DISEASE", 114, 133], ["diabetes", "DISEASE", 138, 146], ["physical inactivity", "DISEASE", 196, 215], ["alcohol", "CHEMICAL", 217, 224], ["alcohol", "CHEMICAL", 217, 224], ["cancer", "CANCER", 106, 112], ["tobacco", "ORGANISM", 183, 190], ["alcohol", "SIMPLE_CHEMICAL", 217, 224], ["\"lifestyle\" diseases", "PROBLEM", 33, 53], ["cardiovascular disease", "PROBLEM", 82, 104], ["cancer", "PROBLEM", 106, 112], ["respiratory disease", "PROBLEM", 114, 133], ["diabetes", "PROBLEM", 138, 146], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["cancer", "OBSERVATION", 106, 112], ["respiratory disease", "OBSERVATION", 114, 133]]], ["I argue that the current concern with NCDs, and the transition from international to global health more generally, coincides with the historical rise of economic rationalities in the field of world health over the last 25 years.IntroductionI begin by comparing two prominent moments in the history of world healththe 1978 Alma-Ata Declaration, in which the WHO reaffirmed its commitment to the goal of \"health for all by the year 2000,\" and the 2013 High Level Meeting of the UN General Assembly at which Non-communicable Diseases were declared to be a grave threat to the global economy.", [["NCDs", "DISEASE", 38, 42], ["Non-communicable Diseases", "PROBLEM", 505, 530]]], ["The contrast between these two moments illustrates the central question of this chapter: How did the dominant conceptualization of health shift from a legitimate end in itself to something that should be maximized in service to the economy?", [["central", "OBSERVATION_MODIFIER", 55, 62], ["dominant", "OBSERVATION_MODIFIER", 101, 109]]], ["One DALY is equivalent to a year of healthy life lost to either premature death or to disability.", [["premature death", "DISEASE", 64, 79], ["disability", "DISEASE", 86, 96], ["premature death", "PROBLEM", 64, 79]]], ["It represents an internationally standardized quantum of ill health used to measure the global incidence of health and disease and to perform cost-effective analyses on potential health care interventions.", [["disease", "PROBLEM", 119, 126], ["potential health care interventions", "TREATMENT", 169, 204], ["global", "OBSERVATION_MODIFIER", 88, 94]]], ["The shift from diseasespecific mortality statistics to DALY calculations brought the global burden of NCDs into clear focus.", [["NCDs", "DISEASE", 102, 106], ["The shift", "PROBLEM", 0, 9], ["global", "OBSERVATION_MODIFIER", 85, 91], ["burden", "OBSERVATION_MODIFIER", 92, 98], ["clear", "OBSERVATION_MODIFIER", 112, 117], ["focus", "OBSERVATION", 118, 123]]], ["However, the DALY method by which NCDs became a global health priority relies on a particular economic valuing of human life.", [["NCDs", "DISEASE", 34, 38], ["human", "ORGANISM", 114, 119], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["human life", "TREATMENT", 114, 124]]], ["I argue that the DALY metric explains the rise of NCDs on the global health agenda and, more fundamentally, illustrates the rise economic rationalities in the field of global health over the last 25 years.From \"Health for All\" to \"Health as Investment\"In September 2011, the United Nations General Assembly convened a high-level meeting to address the prevention and control of non-communicable diseases (NCDs).", [["NCDs", "DISEASE", 50, 54], ["non-communicable diseases", "DISEASE", 378, 403], ["NCDs", "DISEASE", 405, 409], ["non-communicable diseases", "PROBLEM", 378, 403]]], ["It was only the second time in history that such a meeting had been devoted to a topic related to health, the first having been in response to the HIV/AIDs pandemic a decade earlier.", [["HIV/AIDs", "DISEASE", 147, 155]]], ["Unlike the earlier meeting, at which the vast majority of the burden of HIV/AIDs was acknowledged to fall on the countries of Sub-Saharan Africa, the 2011 summit presented the threat posed by NCDs as universal (United Nations General Assembly 2001) .", [["HIV/AIDs", "DISEASE", 72, 80], ["NCDs", "DISEASE", 192, 196], ["HIV", "ORGANISM", 72, 75], ["HIV", "SPECIES", 72, 75], ["HIV/AIDs", "PROBLEM", 72, 80]]], ["Far from the diseases of affluence that cancers, diabetes, and hypertension were once portrayed to be, NCDs had by late 2011 come to occupy a central place on the global health agenda.", [["cancers", "ANATOMY", 40, 47], ["cancers", "DISEASE", 40, 47], ["diabetes", "DISEASE", 49, 57], ["hypertension", "DISEASE", 63, 75], ["NCDs", "DISEASE", 103, 107], ["cancers", "CANCER", 40, 47], ["cancers", "PROBLEM", 40, 47], ["diabetes", "PROBLEM", 49, 57], ["hypertension", "PROBLEM", 63, 75], ["diseases", "OBSERVATION", 13, 21], ["cancers", "OBSERVATION", 40, 47], ["diabetes", "OBSERVATION", 49, 57], ["hypertension", "OBSERVATION", 63, 75]]], ["The precise kind of threat that NCDs were seen to present was not limited to the domain of health: the UN Resolution adopted by the General Assembly declared that \"the global burden and threat of non-communicable diseases constitutes one of the major challenges for development in the twenty-first century\" and that \"non-communicable diseases are a threat to the economies of many Member States\" (United Nations General Assembly 2012).", [["NCDs", "DISEASE", 32, 36], ["non-communicable diseases", "DISEASE", 196, 221], ["communicable diseases", "DISEASE", 321, 342], ["non-communicable diseases", "PROBLEM", 196, 221], ["non-communicable diseases", "PROBLEM", 317, 342], ["NCDs", "OBSERVATION", 32, 36]]], ["A report by the World Health Organization (WHO) and the World Economic Forum (WEF) published to coincide with the UN NCD summit similarly warned that \"The economic consequences of NCDs are staggering\" with projected losses to low and middle income countries surpassing 4% of their annual output (\"From Burden to 'Best Buys:' Reducing the Economic Impact of Non-Communicable Diseases in Low-and Middle-Income Countries\" 2011, 3).", [["NCDs", "DISEASE", 180, 184], ["Non-Communicable Diseases", "PROBLEM", 357, 382], ["Non-Communicable Diseases", "OBSERVATION", 357, 382]]], ["Another report projected that the cost of NCDs to the global economy would exceed US$30 trillion over the next 20 years (Bloom et al. 2011, 5) .", [["NCDs", "DISEASE", 42, 46]]], ["By contrast, the cost of implementing a range of \"best buy\" interventions to prevent NCDs was low.", [["NCDs", "DISEASE", 85, 89], ["interventions", "TREATMENT", 60, 73], ["NCDs", "PROBLEM", 85, 89]]], ["The report continued: \"[\u2026] the return on this investment will be many millions of avoided premature deaths [\u2026and] many billions of dollars of additional output\" (2011, 3).", [["deaths", "DISEASE", 100, 106], ["premature deaths", "PROBLEM", 90, 106]]], ["NCDs are here positioned by the UN, by the WHO and by the WEF as a threat to both the health of the population and as a threat to the economy.", [["NCDs", "DISEASE", 0, 4]]], ["Conversely, strategies to combat NCDs are imaged as a solid investment in health and in economic growth with an expected yield of positive future returns.From \"Health for All\" to \"Health as Investment\"Just twenty-five earlier, in 1978, the World Health Organization celebrated the thirtieth anniversary of its founding with a conference on primary health care at Alma-Ata in the Soviet Union.", [["NCDs", "DISEASE", 33, 37]]], ["There, the famous Alma-Ata declaration was made in which the WHO reaffirmed that \"health, which is a state of complete physical, mental and social wellbeing, and not merely the absence of disease or infirmity, is a fundamental human right.\"", [["infirmity", "DISEASE", 199, 208], ["human", "ORGANISM", 227, 232], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 227, 232], ["disease", "PROBLEM", 188, 195]]], ["In contrast to the UN NCD Declaration in 2013, this earlier declaration positioned health as both a human right and as a \"most important world-wide social goal\" -one that the resources of the economic sector must be harnessed to support.From \"Health for All\" to \"Health as Investment\"How did the conceptualization of health that underpins world health efforts transition from an end-in-itself to a means towards economic growth?", [["human", "ORGANISM", 100, 105], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["right", "ANATOMY_MODIFIER", 106, 111]]], ["Put differently, what explains the economization of global health over the past 25 years?World Health and the World BankThroughout the 1980s the field of international health was beset by a number of tensions: debate over comprehensive vs selective primary health care, vertical vs horizontal approaches to health interventions, and budgetary crisis as well as crises of legitimacy at the World Health Organization.", [["health interventions", "TREATMENT", 307, 327], ["budgetary crisis", "PROBLEM", 333, 349]]], ["Although the conference at Alma-Ata represented a high point in the history of the WHO, it also marked the beginning of a long, slow decline in the organization's prominence.", [["a long, slow decline in the organization's prominence", "PROBLEM", 120, 173], ["marked", "OBSERVATION_MODIFIER", 96, 102], ["slow", "OBSERVATION_MODIFIER", 128, 132], ["decline", "OBSERVATION_MODIFIER", 133, 140], ["prominence", "OBSERVATION", 163, 173]]], ["As opposed to what was now termed \"Comprehensive Primary Health Care\" (CPHP), these actors articulated a vision of \"Selective Primary Health Care\" (SPHC) emphasizing specific, low cost technical interventions that were limited in scope and easy to monitor and evaluate (Balabanova et al. 2013; Walsh and Warren 1979) .", [["low cost technical interventions", "TREATMENT", 176, 208]]], ["Specifically, SPHC advocated a four-pronged approach to reducing child mortality known by the acronym GOBI: Growth monitoring (to ensure early detecting of childhood malnutrition), Oral Rehydration Solutions (for diarrheal diseases), Breastfeeding (for improved infant survival and natural family planning) and Immunization against certain communicable diseases.", [["malnutrition", "DISEASE", 166, 178], ["diarrheal diseases", "DISEASE", 213, 231], ["communicable diseases", "DISEASE", 340, 361], ["a four-pronged approach", "TREATMENT", 29, 52], ["Growth monitoring", "TEST", 108, 125], ["childhood malnutrition", "PROBLEM", 156, 178], ["Oral Rehydration Solutions", "TREATMENT", 181, 207], ["diarrheal diseases", "PROBLEM", 213, 231], ["natural family planning", "TREATMENT", 282, 305], ["Immunization", "TREATMENT", 311, 323], ["certain communicable diseases", "PROBLEM", 332, 361]]], ["The growing tension between advocates of SPHC and CPHC caused considerable tension at the WHO.World Health and the World BankAgainst this backdrop, the World Bank \"moved confidently into the vacuum created by an increasingly ineffective WHO\" (Brown et al. 2006, 86) .", [["SPHC", "DISEASE", 41, 45], ["CPHC", "DISEASE", 50, 54], ["The growing tension", "PROBLEM", 0, 19], ["SPHC", "PROBLEM", 41, 45], ["CPHC", "TREATMENT", 50, 54], ["considerable tension", "PROBLEM", 62, 82], ["growing", "OBSERVATION_MODIFIER", 4, 11], ["tension", "OBSERVATION_MODIFIER", 12, 19], ["considerable", "OBSERVATION_MODIFIER", 62, 74], ["tension", "OBSERVATION", 75, 82]]], ["Although the Bank's initial interest in health extended only to population control, by the early 1980s the newly founded Population, Health and Nutrition Department began lending for stand-alone alone health programs on the rationale that enhanced health and nutrition would lead to increased economic growth (World Bank 1980).", [["increased economic growth", "PROBLEM", 283, 308]]], ["However, with World Bank money came their associated structural adjustment policies, which, in the domain of health focused on more efficient use of available resources and an increased role for the private sector in financing health services -all in service of promoting health for economic growth.", [["economic growth", "PROBLEM", 283, 298]]], ["2 The changing structural organization of international health coincided with a shift in the field's conceptualization of its primary targets due to \"health transition.\"", [["structural", "OBSERVATION_MODIFIER", 15, 25], ["organization", "OBSERVATION_MODIFIER", 26, 38]]], ["A pretransitional environment dominated by high fertility and high mortality was seen to be giving way to a low mortality, low fertility environment (Frenk et al. 1989) .", [["A pretransitional environment", "PROBLEM", 0, 29], ["high fertility", "PROBLEM", 43, 57], ["high mortality", "PROBLEM", 62, 76], ["high fertility", "OBSERVATION", 43, 57]]], ["While the health transition held general implications for the orientation of the world health agenda -away from population control and towards diseases of old-age, for examplethe precise consequences of the transition for the global incidence of disease and for the exact interventions necessary to curb its spread were unknown.", [["disease", "PROBLEM", 246, 253], ["the exact interventions", "TREATMENT", 262, 285], ["disease", "OBSERVATION", 246, 253]]], ["This knowledge deficit presented a two-fold problem for the Bank.", [["This knowledge deficit", "PROBLEM", 0, 22], ["a two-fold problem", "PROBLEM", 33, 51]]], ["Second, in the absence of systematic estimates of the global burden of disease, statistics on disease prevalence were frequently provided by disease-specific advocates.", [["the global burden of disease", "PROBLEM", 50, 78], ["global", "OBSERVATION_MODIFIER", 54, 60], ["burden", "OBSERVATION_MODIFIER", 61, 67], ["disease", "OBSERVATION", 71, 78]]], ["The Bank thus undertook a wide-reaching Health Sector Priorities Review which yielded a constellation of studies -most significantly the Disease Control Priorities Project (DCPP) (Jamison et al. 1993 ) and the Global Burden of Disease Study (GBD) (Murray and Lopez 1996) .", [["Burden of Disease", "DISEASE", 217, 234], ["studies", "TEST", 105, 112], ["Global", "OBSERVATION_MODIFIER", 210, 216], ["Burden", "OBSERVATION_MODIFIER", 217, 223], ["Disease", "OBSERVATION", 227, 234]]], ["Importantly for my purposes, the World Development Report 1993 (WDR 1993) also introduced the Disability Adjusted Life Year metric.The DALY MetricThe architects of the DALY metric devised their new method for measuring the global burden of disease in order to account for the \"full loss of healthy life\" due to disease, death and disability on a global scale and to determine global health priorities according to cost-benefit analyses (Lopez 2005) .", [["death", "DISEASE", 320, 325], ["disability", "DISEASE", 330, 340], ["disease", "PROBLEM", 240, 247], ["disease", "PROBLEM", 311, 318], ["death", "PROBLEM", 320, 325], ["a global scale", "TEST", 344, 358], ["new", "OBSERVATION_MODIFIER", 194, 197], ["global", "OBSERVATION_MODIFIER", 223, 229], ["burden", "OBSERVATION_MODIFIER", 230, 236], ["disease", "OBSERVATION", 240, 247]]], ["Previous attempts to gauge the relative importance of different diseases used mortality statistics, disease prevalence rates, or risk of death calculations to determine the number of deaths due to various diseases (Feachem et al. 1992) .", [["death", "DISEASE", 137, 142], ["deaths", "DISEASE", 183, 189], ["different diseases", "PROBLEM", 54, 72], ["disease prevalence rates", "PROBLEM", 100, 124], ["death calculations", "PROBLEM", 137, 155], ["various diseases", "PROBLEM", 197, 213]]], ["The DALY metric, in contrast, sought to account also for the burden of diseases and conditions that may not be fatal, but by virtue of their duration and disabling effects contributed to economic \"losses\" in the form of diminished productivity and strain on health systems.", [["the burden of diseases and conditions", "PROBLEM", 57, 94], ["disabling effects", "PROBLEM", 154, 171], ["economic \"losses\"", "PROBLEM", 187, 204], ["diminished productivity and strain on health systems", "PROBLEM", 220, 272], ["diseases", "OBSERVATION", 71, 79], ["may not be", "UNCERTAINTY", 100, 110], ["diminished", "OBSERVATION_MODIFIER", 220, 230], ["productivity", "OBSERVATION", 231, 243]]], ["3 The DALY metric thus used \"life-years\" as a smaller and more commensurable unit than calculations made in terms of individual human lives.", [["human", "ORGANISM", 128, 133], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133]]], ["4 In its simplest presentation the DALY metric expresses \"years of life lost to premature death and years lived with a disability of specified severity and duration\" (Murray and Lopez 1996b, 7) .DALYs = + YLL YLD3 Ayo Wahlberg and Nikolas Rose have analyzed the DALY metric and disease burden concept as part of a longer history of what they call the \"governmentalization of living\" (Wahlberg and Rose 2015) .", [["premature death", "DISEASE", 80, 95], ["premature death", "PROBLEM", 80, 95], ["disease burden", "PROBLEM", 278, 292]]], ["4 While not the focus of the present paper, it is important to note also that by disaggregating lives into \"life years\", the DALY metric also provided a unit-measure with which to perform cost effectiveness analyses without appearing to put a dollar value on individual human lives.", [["human", "ORGANISM", 270, 275], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 270, 275]]], ["However, a more technical description can be found in the WDR 1993, which explains that the DALY metric \"measures the present value of the future stream of disability-free life lost as a result of death, disease, or injury\" (World Bank 1993, 27) .", [["disability", "DISEASE", 156, 166], ["death", "DISEASE", 197, 202], ["death", "PROBLEM", 197, 202], ["disease", "PROBLEM", 204, 211], ["injury", "PROBLEM", 216, 222]]], ["This measurement is made using a number of econometric techniques.", [["This measurement", "TEST", 0, 16], ["econometric techniques", "TREATMENT", 43, 65]]], ["It was incorporated into the DALY metric by \"consensus judgment\" in order to reflect the idea that \"most societies attach more importance to a year of life lived by a young or middle-aged adult than to a year of life lived by a child or an elderly person\" (World Bank 1993, 26 & 213) .", [["person", "SPECIES", 248, 254]]], ["However, even if life was held to have the same intrinsic value at every age, one might still \"attach greater importance to years of productive adult life\" because of the importance of adults as \"net producers\" i.e. for their increased human capital and resulting contribution to economic growth (Murray and Lopez 1996) .", [["human", "ORGANISM", 236, 241], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["their increased human capital", "PROBLEM", 220, 249], ["economic growth", "PROBLEM", 280, 295]]], ["The precise values used for DALY calculations were chosen so that the total number of DALYs is the same as though uniform age weights had been used (World Bank 1993, 213) .", [["DALY calculations", "TREATMENT", 28, 45]]], ["But age weighting redistributes DALYs away from the early and later years and concentrate them on the middle, economically productive years of life -i.e. those years most critical to the Bank's priority of economic growth.DiscountingThe DALY metric also incorporates a discount rate (of 3%) such that future years of healthy life are valued at progressively lower levels into the future.", [["economic growth", "PROBLEM", 206, 221], ["a discount rate", "TEST", 267, 282], ["redistributes", "OBSERVATION_MODIFIER", 18, 31], ["DALYs", "OBSERVATION", 32, 37], ["middle", "ANATOMY_MODIFIER", 102, 108]]], ["Like age weighting, discounting results in the relatively greater valuing of economically productive middle years of life because the future years of life lost from 5 Other components of the DALY metric include the severity weights that are used for calculating the impact of disability and the use of a global standardized life expectancy.", [["disability", "DISEASE", 276, 286], ["the severity weights", "PROBLEM", 211, 231], ["a global standardized life expectancy", "TREATMENT", 302, 339]]], ["Disability weights have been debated extensively in the scientific literature (Anand and Hanson 1997; Anand et al. 2004) .", [["Disability weights", "PROBLEM", 0, 18]]], ["For my purposes here, it is important simply to note that economic productivity is also central to the determination of disability weights in so far as the ability to perform in one's occupation is a key feature of the disability weighting scale. childhood deaths is discounted over a longer period.", [["disability", "DISEASE", 120, 130], ["deaths", "DISEASE", 257, 263], ["disability weights", "PROBLEM", 120, 138]]], ["The contribution of childhood deaths to the global burden of disease is thus given relatively less numerical significance.", [["deaths", "DISEASE", 30, 36], ["childhood deaths", "PROBLEM", 20, 36], ["disease", "PROBLEM", 61, 68], ["global", "OBSERVATION_MODIFIER", 44, 50], ["burden", "OBSERVATION", 51, 57], ["disease", "OBSERVATION", 61, 68]]], ["As the GBD authors acknowledge \"[\u2026] higher discount rates reduce the importance of premature deaths at young ages in relation to those at older ages\" (WDR 214).DiscountingThe incorporation of age weighting and discounting functions into the DALY metric minimizes the contribution of childhood deaths to the global burden of disease and puts relatively greater value on the middle economically productive years of life -precisely those years deemed most important by the Bank for increasing economic growth.", [["deaths", "DISEASE", 93, 99], ["deaths", "DISEASE", 293, 299], ["premature deaths", "PROBLEM", 83, 99], ["the global burden of disease", "PROBLEM", 303, 331], ["increasing economic growth", "PROBLEM", 479, 505], ["global", "OBSERVATION_MODIFIER", 307, 313], ["burden", "OBSERVATION_MODIFIER", 314, 320], ["disease", "OBSERVATION", 324, 331]]], ["Figure 13 .1 illustrates the age weighting function and the combined impact of age weighting and discounting on the resulting DALYs lost to death at different ages across the life course.DiscountingThe relatively greater weighting of the middle, economically productive years of life in DALY calculations reflects a central tenet of the field of health economics as it has developed since the 1970s and 1980s: the conceptualization of health as a form of human capital.Health as Human CapitalEach of the technical dimensions of the DALY metrics is underpinned by a general conceptualization of health as a form of \"human capital\"-a Nobel-prize winning approach within the field of economics developed by the Chicago School's Theodore Schultz and Gary Becker (Becker 1962; Schultz 1961) .", [["death", "DISEASE", 140, 145], ["human", "ORGANISM", 455, 460], ["Human", "ORGANISM", 479, 484], ["human", "ORGANISM", 615, 620], ["human", "SPECIES", 455, 460], ["Human", "SPECIES", 479, 484], ["human", "SPECIES", 615, 620], ["human", "SPECIES", 455, 460], ["human", "SPECIES", 615, 620], ["relatively", "OBSERVATION_MODIFIER", 202, 212], ["greater", "OBSERVATION_MODIFIER", 213, 220], ["middle", "ANATOMY_MODIFIER", 238, 244], ["central tenet", "OBSERVATION_MODIFIER", 316, 329]]], ["Although human capital theory met with resistance and controversy upon its initial introduction and Bank 1993, 26) development in the 1950s and 1960s, by the 1990s, it had become a central tenet of both micro and macro economic theory and key to the rapid expansion of the field of economics through so-called economic imperialism (Becker 1992; Fourcade 2006; Fourcade-Gourinchas 2001; Mitchell 2006) .Health as Human CapitalBecker defined human capital as those \"activities that influence future real income through the imbedding of resources in people\" including the knowledge, skills, dispositions and health that are embodied in people that make them economically productive (1962, 9) .", [["human", "ORGANISM", 9, 14], ["Human", "ORGANISM", 412, 417], ["human", "ORGANISM", 440, 445], ["people", "ORGANISM", 547, 553], ["people", "ORGANISM", 633, 639], ["human", "SPECIES", 9, 14], ["Human", "SPECIES", 412, 417], ["human", "SPECIES", 440, 445], ["people", "SPECIES", 547, 553], ["people", "SPECIES", 633, 639], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 440, 445], ["rapid", "OBSERVATION_MODIFIER", 250, 255], ["expansion", "OBSERVATION_MODIFIER", 256, 265]]], ["Some of the ways to invest in one's human capital, Becker argued \"include schooling, on-the-job training, medical care, vitamin consumption, and acquiring information about the economic system\" (1962, 9) .", [["vitamin", "CHEMICAL", 120, 127], ["vitamin", "CHEMICAL", 120, 127], ["human", "ORGANISM", 36, 41], ["vitamin", "SIMPLE_CHEMICAL", 120, 127], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["medical care", "TREATMENT", 106, 118], ["vitamin consumption", "TREATMENT", 120, 139]]], ["\"But all improve the physical and mental abilities of people and thereby raise real income prospects\" (Becker 1962, 9) .Health as Human CapitalWhile Becker acknowledged the importance of health as a form of human capital, the concept was more fully theorized by Becker's student Michael Grossman (Grossman 1972 (Grossman , 2004 .", [["people", "ORGANISM", 54, 60], ["Human", "ORGANISM", 130, 135], ["human", "ORGANISM", 207, 212], ["people", "SPECIES", 54, 60], ["Human", "SPECIES", 130, 135], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212]]], ["First, as a consumption commodity it \"enters into their preference functions,\" that is, people prefer a state of health over a state of ill health.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94]]], ["Second, and importantly for the argument here, health is conceptualized as an investment commodity because it \"determines the total amount of time available for market and nonmarket activities [\u2026 such that] an increase in the stock of health reduces the time lost from these activities [i.e. time away from market and non-market activities]\" (Grossman 1972, 225) .", [["increase", "OBSERVATION_MODIFIER", 210, 218]]], ["Investing in one's health extends the duration of possible participation in market and non-market activity and maximizes the term over which investment in one's human capital can be realized.Health as Human CapitalThe DALY metric was designed for the purposes of carrying out cost-benefit analyses of potential health interventions so as to design economically rational health systems.", [["human", "ORGANISM", 161, 166], ["Human", "ORGANISM", 201, 206], ["human", "SPECIES", 161, 166], ["Human", "SPECIES", 201, 206], ["human", "SPECIES", 161, 166], ["potential health interventions", "TREATMENT", 301, 331]]], ["But more than just facilitating cost-benefit analyses, the DALY metric accomplishes an economization of health by imagining health as a form of human capital.NDCs on the Global Health AgendaBecause of the higher valuing of economically productive middle years of life in DALY calculations, disease of middle age -notably NCDs -achieved greater prominence in the Global Burden of Disease (GBD) results Lopez 1996, World Bank 1993) .", [["NCDs", "DISEASE", 321, 325], ["Burden of Disease", "DISEASE", 369, 386], ["human", "ORGANISM", 144, 149], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["disease of middle age", "PROBLEM", 290, 311], ["NCDs", "PROBLEM", 321, 325], ["greater prominence", "PROBLEM", 336, 354], ["the Global Burden of Disease", "PROBLEM", 358, 386], ["middle", "ANATOMY_MODIFIER", 301, 307], ["greater", "OBSERVATION_MODIFIER", 336, 343], ["prominence", "OBSERVATION", 344, 354], ["Global", "OBSERVATION_MODIFIER", 362, 368], ["Burden", "OBSERVATION_MODIFIER", 369, 375], ["Disease", "OBSERVATION", 379, 386]]], ["Before the introduction of the DALY metric, the thencurrent most comprehensive study of adult health worldwide concluded that \"mortality from non-communicable diseases declines as overall mortality declines\" (Feachem et al. 1992, 94) .", [["non-communicable diseases", "DISEASE", 142, 167], ["non-communicable diseases", "PROBLEM", 142, 167]]], ["This suggested that as countries' death rates declined as they entered \"health transition\" so too would NCDs.", [["death", "DISEASE", 34, 39], ["NCDs", "DISEASE", 104, 108]]], ["However, after the introduction of the DALY metric just a few years later, the GBD would report that NCDs represented the single largest category of DALYs lost worldwide -greater than either communicable diseases or injuries (Murray and Lopez 1996) .", [["NCDs", "DISEASE", 101, 105], ["communicable diseases", "DISEASE", 191, 212], ["injuries", "DISEASE", 216, 224], ["communicable diseases", "PROBLEM", 191, 212], ["injuries", "PROBLEM", 216, 224]]], ["Furthermore, it would predict that by 2020 NCDs would account for more than 70% of deaths in developing regions (Murray and Lopez 1996) .", [["NCDs", "DISEASE", 43, 47], ["deaths", "DISEASE", 83, 89]]], ["At the same time, the Disease Control Priorities Project (DCPP), also sponsored by the World Bank, would make a strong case for cost effectiveness of health interventions designed to mitigate NCD risksnotably those directed towards personal behavior change (Jamison et al. 1993) .NDCs on the Global Health AgendaThe introduction of the DALY metric by the World Bank's World Development Report 1993: Investing in health brought NCDs into clear focus on the global health agenda.", [["NCDs", "DISEASE", 427, 431], ["health interventions", "TREATMENT", 150, 170], ["Disease", "OBSERVATION", 22, 29]]], ["And this focus was further institutionalized in the early 2000s when the WHO officially adopted the DALY metric for purposes of disease quantification and cost-effectiveness analyses for purposes of priority setting (World Health Organization 2000) .", [["disease quantification", "TEST", 128, 150], ["cost-effectiveness analyses", "TEST", 155, 182]]], ["By September 2011, NCDs had come to occupy such a central position on the global health agenda as to warrant a UN High Level Summit meeting -only the second such meeting in the history of the UN.ConclusionThe creation of the DALY metric by the World Bank in the early 1990s brought NCDs firmly onto the global health agenda.", [["NCDs", "DISEASE", 19, 23], ["NCDs", "DISEASE", 282, 286]]], ["However, as this paper has suggested, the DALY logic by which NCDs became a global health priority depends on a vision of health as a form of human capital and as a site of investment.", [["NCDs", "DISEASE", 62, 66], ["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147]]], ["The political implications of the DALY metric -the redistribution of DALYs away from childhood disease and diseases of old age and towards the middle, economically productive years of life -are frequently obscured by the apparent objectivity of the numbers produced by DALY calculations.", [["childhood disease", "PROBLEM", 85, 102], ["diseases", "PROBLEM", 107, 115], ["political", "OBSERVATION_MODIFIER", 4, 13], ["redistribution", "OBSERVATION_MODIFIER", 51, 65], ["middle", "ANATOMY_MODIFIER", 143, 149]]], ["Yet these implications remain inseparable from the rising prominence of the World Bank in world health affairs since the late 1980s, its efforts to restructure health systems according to cost effectiveness, and its greater valuing of the economically productive middle years of life so as to prioritize health for economic growth.ConclusionMore generally, the creation of the DALY metric and concomitant rise of NCDs as a global health priority coincides with the broader shift from international health to global health that has occurred over the last 25 years.", [["NCDs", "DISEASE", 413, 417], ["economic growth", "PROBLEM", 315, 330], ["rising", "OBSERVATION_MODIFIER", 51, 57], ["prominence", "OBSERVATION", 58, 68], ["greater", "OBSERVATION_MODIFIER", 216, 223]]], ["In contrast to a post-war vision of health as a human right and social good -a vision that came to be enshrined in the Alta Ata declaration of 1978 -the contemporary era of global health conceptualizes health as a form of human capital and as a site of investment.", [["human", "ORGANISM", 48, 53], ["human", "ORGANISM", 222, 227], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 222, 227], ["right", "ANATOMY_MODIFIER", 54, 59]]]], "PMC7525345": [["IntroductionAs the coronavirus disease 2019 (COVID-19) pandemic continues across the United States, a critical issue for practicing oncologists is how to continue cancer care while protecting patients.1 To continue care for patients while also minimizing exposure to health care staff, the Weill Cornell Medicine Division of Hematology and Medical Oncology created separate units for patients with confirmed COVID-19, patients with symptomatic but unconfirmed COVID-19, and asymptomatic patients with no known high-risk COVID-19 exposures.2 Patients were contacted prior to their appointment and triaged based on their COVID-19 risk status.", [["cancer", "ANATOMY", 163, 169], ["coronavirus disease", "DISEASE", 19, 38], ["COVID-19", "CHEMICAL", 45, 53], ["cancer", "DISEASE", 163, 169], ["coronavirus", "ORGANISM", 19, 30], ["cancer", "CANCER", 163, 169], ["patients", "ORGANISM", 192, 200], ["patients", "ORGANISM", 224, 232], ["patients", "ORGANISM", 384, 392], ["patients", "ORGANISM", 418, 426], ["patients", "ORGANISM", 487, 495], ["Patients", "ORGANISM", 541, 549], ["patients", "SPECIES", 192, 200], ["patients", "SPECIES", 224, 232], ["patients", "SPECIES", 384, 392], ["patients", "SPECIES", 418, 426], ["patients", "SPECIES", 487, 495], ["Patients", "SPECIES", 541, 549], ["the coronavirus disease", "PROBLEM", 15, 38], ["COVID", "TEST", 45, 50], ["pandemic", "PROBLEM", 55, 63], ["cancer care", "TREATMENT", 163, 174], ["COVID", "TEST", 408, 413], ["COVID", "TEST", 460, 465], ["known high-risk COVID", "PROBLEM", 504, 525], ["their COVID", "TEST", 613, 624], ["coronavirus disease", "OBSERVATION", 19, 38]]], ["To understand the success of our clinical screening and triaging procedures, we implemented a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing protocol in asymptomatic patients who required cancer care across the Division of Hematology and Medical Oncology.MethodsThis quality improvement study, approved by Weill Cornell Medicine, follows the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting guideline.", [["cancer", "ANATOMY", 210, 216], ["acute respiratory syndrome coronavirus", "DISEASE", 101, 139], ["cancer", "DISEASE", 210, 216], ["patients", "ORGANISM", 188, 196], ["cancer", "CANCER", 210, 216], ["patients", "SPECIES", 188, 196], ["severe acute respiratory syndrome coronavirus", "SPECIES", 94, 139], ["SARS-CoV", "SPECIES", 143, 151], ["our clinical screening", "TEST", 29, 51], ["triaging procedures", "TREATMENT", 56, 75], ["a severe acute respiratory syndrome coronavirus", "PROBLEM", 92, 139], ["testing protocol", "TEST", 155, 171], ["cancer care", "TREATMENT", 210, 221], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127]]], ["Informed consent was waived because data were deidentified, per institutional policy.MethodsPatients were considered asymptomatic if they had no recent fever (defined as body temperature \u2265100.5 \u00b0F for \u22655 days); no COVID-19 symptoms, which included cough, headache, loss of taste, and shortness of breath3; or high risk exposure (eg, contact with an individual with confirmed COVID-19, nursing home stay, or hospitalization) within 14 days.", [["body", "ANATOMY", 170, 174], ["fever", "DISEASE", 152, 157], ["cough", "DISEASE", 248, 253], ["headache", "DISEASE", 255, 263], ["loss of taste", "DISEASE", 265, 278], ["shortness of breath3", "DISEASE", 284, 304], ["Patients", "ORGANISM", 92, 100], ["body", "ORGANISM_SUBDIVISION", 170, 174], ["Patients", "SPECIES", 92, 100], ["recent fever", "PROBLEM", 145, 157], ["body temperature", "TEST", 170, 186], ["COVID-19 symptoms", "PROBLEM", 214, 231], ["cough", "PROBLEM", 248, 253], ["headache", "PROBLEM", 255, 263], ["loss of taste", "PROBLEM", 265, 278], ["shortness of breath3", "PROBLEM", 284, 304], ["fever", "OBSERVATION", 152, 157]]], ["Diagnosis of COVID-19 was confirmed using SARS-CoV-2 nasal swab polymerase chain reaction (PCR) testing (Cobas 6800; Roche Diagnostics) and SARS-CoV-2 IgM and IgG serological tests (Pylon 3D; ET HealthCare).4 Patients were retested every 1 to 2 weeks.", [["SARS-CoV-2 IgM", "GENE_OR_GENE_PRODUCT", 140, 154], ["Patients", "ORGANISM", 209, 217], ["COVID-19", "DNA", 13, 21], ["IgM", "PROTEIN", 151, 154], ["IgG", "PROTEIN", 159, 162], ["Patients", "SPECIES", 209, 217], ["SARS-CoV", "SPECIES", 140, 148], ["COVID", "TEST", 13, 18], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["nasal swab polymerase chain reaction", "TEST", 53, 89], ["PCR", "TEST", 91, 94], ["Cobas", "TEST", 105, 110], ["Roche Diagnostics", "TEST", 117, 134], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["IgM", "TEST", 151, 154], ["IgG serological tests", "TEST", 159, 180], ["nasal", "ANATOMY", 53, 58]]], ["Rates of positive SARS-CoV-2 PCR and COVID-19 serological tests and 95% CIs are reported, using the 2-sided Clopper-Pearson (exact) 95% CI.", [["Rates", "TEST", 0, 5], ["positive SARS", "PROBLEM", 9, 22], ["CoV", "TEST", 23, 26], ["PCR", "TEST", 29, 32], ["COVID", "TEST", 37, 42], ["serological tests", "TEST", 46, 63], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["SARS", "OBSERVATION", 18, 22], ["sided", "ANATOMY_MODIFIER", 102, 107]]], ["Statistical analyses were conducted using Stata statistical software version 13.1 (StataCorp).ResultsFrom April 30 through June 2, 2020, we performed 621 SARS-CoV-2 PCR tests on 537 asymptomatic patients (272 [50.7%] men) with hematologic or solid tumor malignant neoplasms (Table 1).", [["hematologic", "ANATOMY", 227, 238], ["solid tumor malignant neoplasms", "ANATOMY", 242, 273], ["tumor", "DISEASE", 248, 253], ["malignant neoplasms", "DISEASE", 254, 273], ["patients", "ORGANISM", 195, 203], ["men", "ORGANISM", 217, 220], ["hematologic", "CANCER", 227, 238], ["solid tumor malignant neoplasms", "CANCER", 242, 273], ["patients", "SPECIES", 195, 203], ["men", "SPECIES", 217, 220], ["Statistical analyses", "TEST", 0, 20], ["Stata statistical software version", "TEST", 42, 76], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["PCR tests", "TEST", 165, 174], ["asymptomatic", "TEST", 182, 194], ["hematologic or solid tumor malignant neoplasms", "PROBLEM", 227, 273], ["solid", "OBSERVATION_MODIFIER", 242, 247], ["tumor", "OBSERVATION", 248, 253]]], ["Our patients were geographically representative of New York, New York, and surrounding areas, and more than 90% of patients were receiving active cytotoxic or targeted therapy.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 115, 123], ["active cytotoxic", "TREATMENT", 139, 155], ["targeted therapy", "TREATMENT", 159, 175], ["New", "OBSERVATION_MODIFIER", 51, 54], ["New", "OBSERVATION_MODIFIER", 61, 64], ["surrounding", "OBSERVATION_MODIFIER", 75, 86], ["areas", "OBSERVATION_MODIFIER", 87, 92]]], ["The rate of SARS-CoV-2 positivity was 0.64% (95% CI, 0.18%-1.64%).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["SARS-CoV", "SPECIES", 12, 20], ["The rate", "TEST", 0, 8], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["CI", "TEST", 49, 51]]], ["This includes 84 patients who had repeated SARS-CoV-2 tests, all of which were negative.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["repeated SARS", "TEST", 34, 47], ["CoV-2 tests", "TEST", 48, 59], ["negative", "OBSERVATION", 79, 87]]], ["Only 4 asymptomatic patients had test results positive for COVID-19, 2 each for hematologic and solid tumor neoplasms.", [["hematologic", "ANATOMY", 80, 91], ["solid tumor neoplasms", "ANATOMY", 96, 117], ["tumor", "DISEASE", 102, 107], ["neoplasms", "DISEASE", 108, 117], ["patients", "ORGANISM", 20, 28], ["hematologic", "CANCER", 80, 91], ["solid tumor neoplasms", "CANCER", 96, 117], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 59, 64], ["hematologic and solid tumor neoplasms", "PROBLEM", 80, 117], ["hematologic", "ANATOMY", 80, 91], ["solid tumor neoplasms", "OBSERVATION", 96, 117]]], ["We also performed serological tests from May 18 to June 2, 2020, on 238 asymptomatic patients.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["serological tests", "TEST", 18, 35]]], ["The rate of COVID-19 prior exposure in our asymptomatic cancer population was 4.23% (95% CI, 2.05%-7.65%) (Table 2).", [["cancer", "ANATOMY", 56, 62], ["cancer", "DISEASE", 56, 62], ["cancer", "CANCER", 56, 62], ["The rate", "TEST", 0, 8], ["COVID", "TEST", 12, 17], ["our asymptomatic cancer population", "PROBLEM", 39, 73], ["CI", "TEST", 89, 91], ["asymptomatic", "OBSERVATION_MODIFIER", 43, 55], ["cancer", "OBSERVATION", 56, 62]]], ["Notably, during this period, the SARS-CoV-2 PCR positivity rate in New York City in early May was 20%.5DiscussionThe findings of this quality improvement study have several important implications.", [["SARS", "DISEASE", 33, 37], ["the SARS", "TEST", 29, 37], ["CoV", "TEST", 38, 41]]], ["While it was clearly prudent to postpone elective procedures and delay care when possible, it is also clear that the risk of COVID-19 is likely to persist for some time.", [["COVID-19", "CHEMICAL", 125, 133], ["elective procedures", "TREATMENT", 41, 60], ["COVID", "TEST", 125, 130]]], ["Cancer care will need to continue, given that further delays will lead to significantly worse outcomes for individual patients6 and other health care crises.", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6], ["Cancer care", "TREATMENT", 0, 11], ["individual patients6 and other health care crises", "PROBLEM", 107, 156]]], ["We observed that the rate of past infection in our clinically screened asymptomatic cancer population was exceedingly low, at approximately 4%, and the rate of SARS-CoV-2 PCR positivity was less than 1%.", [["cancer", "ANATOMY", 84, 90], ["infection", "DISEASE", 34, 43], ["cancer", "DISEASE", 84, 90], ["SARS", "DISEASE", 160, 164], ["cancer", "CANCER", 84, 90], ["SARS-CoV", "SPECIES", 160, 168], ["past infection", "PROBLEM", 29, 43], ["asymptomatic cancer population", "PROBLEM", 71, 101], ["the rate", "TEST", 148, 156], ["SARS", "TEST", 160, 164], ["CoV", "TEST", 165, 168], ["PCR positivity", "TEST", 171, 185], ["infection", "OBSERVATION", 34, 43], ["cancer", "OBSERVATION", 84, 90], ["low", "OBSERVATION_MODIFIER", 118, 121]]], ["While we do not know the reason for this low prevalence rate, it is likely that these highly motivated patients abided to social distancing recommendations, masking, and hygiene.", [["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["this low prevalence rate", "PROBLEM", 36, 60]]], ["We found that patients whose test results were negative for COVID-19 could receive chemotherapy without increasing the risk of contracting the disease, further bolstering the argument that clinicians may resume anticancer therapy in asymptomatic patients.", [["anticancer", "ANATOMY", 211, 221], ["COVID-19", "CHEMICAL", 60, 68], ["patients", "ORGANISM", 14, 22], ["anticancer", "CANCER", 211, 221], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 246, 254], ["COVID", "TEST", 60, 65], ["chemotherapy", "TREATMENT", 83, 95], ["the disease", "PROBLEM", 139, 150], ["anticancer therapy", "TREATMENT", 211, 229], ["disease", "OBSERVATION", 143, 150]]], ["Our quality initiative study was limited by the relatively small sample size of our patients in racial/ethnic minority groups and relatively short patient follow-up.", [["patients", "ORGANISM", 84, 92], ["patient", "ORGANISM", 147, 154], ["patients", "SPECIES", 84, 92], ["patient", "SPECIES", 147, 154], ["Our quality initiative study", "TEST", 0, 28], ["racial/ethnic minority groups", "TREATMENT", 96, 125], ["small", "OBSERVATION_MODIFIER", 59, 64], ["sample", "OBSERVATION_MODIFIER", 65, 71], ["size", "OBSERVATION_MODIFIER", 72, 76]]], ["However, we found that with proper patient education and clinical screening for symptoms or viral exposure, we maintained the outpatient clinical arena largely free of SARS-CoV-2.", [["SARS", "DISEASE", 168, 172], ["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["SARS-CoV", "SPECIES", 168, 176], ["clinical screening", "TEST", 57, 75], ["symptoms", "PROBLEM", 80, 88], ["viral exposure", "PROBLEM", 92, 106], ["CoV", "TEST", 173, 176]]], ["These data provide some reassurance to health care workers and patients that oncological treatment may safely continue.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["oncological treatment", "TREATMENT", 77, 98]]]]}